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The aim of this study is to apply the highly enantioselective alkyne isomerization 
reactions that is developed in our group to construct complex and usefull molucules 
towards natural product synthesis.  
We have found that a Brønsted-base catalyzed tandem isomerization-aza-Michael 
reaction can be used to form useful heterocycles under mild conditions. This efficient 
method was applied to the synthesis of various functionalized heterocycles with 
excellent yields. Tandem isomerization-aza-Michael reaction with alkynyl-amines, 
alkynyl-amide led to interesting piperidines and lactams. Asymmetric version of 
tandem isomerization-aza-Michael reaction using alkynyl-amide was tested to give 
high ee using a chiral bicyclic guanidine as a catalyst. Effort to synthesize larger ring 
sized lactams was carried out although failed. 
We have also found that chiral bicyclic guanidine could catalyze a tandem 
isomerisation intramolecular-Diels-Alder (IMDA) reaction. Interesting and useful 
hydroisoquinolines were obtained with moderate to high ees. The chirality was 
generated at the stage of alkyne isomerisation and transferred efficiently at the [4+2] 
cyclization step. We have also successfully finished the first catalytic enantioselective 
synthesis of alpha-yohimbine starting from the IMDA products.  
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1.1 General introduction to allene  
 Allenes are three-carbon functional groups possessing a 1, 2-diene moiety and 
they are potential precursors in the synthesis of highly complex and strained target 
molecules of biological and industrial importance. Allenes were first synthesized 
in 1887,1 However, the structures were confirmed only in 1954.2 Surprisingly, 
van’t Hoff, in 1875, was able to predict that unsymmetrically substituted allenes 
should be chiral and exist in two enantiomeric forms.3 The initial development of 
allene chemistry was severely impeded by limited synthetic methods and also the 
false notion that such a 1, 2-diene functional group would be highly unstable. 
Since the development of modern analytical technologies, especially IR and 
Raman spectroscopy, allene chemistry is drawing more and more attention from 
organic chemists. A lot of natural products with interesting biological activities  
have been found containing the allene moiety (Scheme 1.1.1).4 
 




 As a class of unique compounds, allenes have two π-orbitals perpendicular to 
each other. They have been shown to demonstrate nice reactivities as well as 
selectivities, which can usually be tuned by electronic or steric effects or the 
nature of the catalysts involved. They are ready to undergo either electrophilic 
addition or nucleophilic addition (Scheme 1.1.2).  Electrophilic addition may 
afford terminal attack and central attack products. The regio- and stereoselectivity 
depends on the steric and electronic effects of the substituents on the allene, the 
nature of the electrophile and solvent effects. However, nucleophilic addition 
usually occurs at the central carbon atom with few exceptions.  
      Electrophilic addition 
                     Nucleophilic addition 
Scheme 1.1.2 Two addition models of allenes  
 Allenes have also been shown to be great precursors for cycloaddition reactions.5 
They are able to afford many complex and interesting molecules via various 
cycloaddition reactions, such as [2+2], [3+2] and [4+2].5 Furthermore,  
intramolecular type cycloaddition usually affords more complex and interesting 
structures which may be synthetically useful in natural product synthesis.  
 This chapter will review the progress on intramolecular conjugate addition and 
intramolecular Diels-Alder cycloaddition of allenes.  




 In 1987, the first example of intramolecular addition of alcohols to 1, 2-allenyl 
sulfoxides was reported by Parsons et al.6 This offered an efficient route for the 
preparation of hydropyrans and spiroketals, which are widely distributed in nature 
and are found in molecules possessing a diverse range of biological activity.7 
 
 
Scheme 1.2.1 Intramolecular Michael addition of alcohol to allene sulphoxide 
 When alcohol 5 was treated with sodium hydride in dry THF, 5-methyl 
-6-(phenylsulfinylmethyl)-3, 4-dihydro-2H-pyran (6) was obtained in 97% yield 
(Scheme 1.2.1). Similarly, when alcohol 7 was treated with sodium hydride in dry 
THF, nucleophilic Michael addition occurred. After removal of the silyl protecting 
group with HF in MeOH, an electrophilic addition was promoted when treating 8 
with catalytic amount of CSA in DCM, which afforded the (4, 5)-spiroketal 9 
(Scheme 1.2.1). An interesting compound 12 of a bicyclic pyran structure was 
also obtained (Scheme 1.2.1). When diol 10, the deprotection product of 7, was 




in 88% yield. After treatment of 11 with sodium hydride in THF, the bicyclic 
pyran 12 was obtained in 50% yield. However, the diastereoisomers are 
inseparable.  
 Another investigation on 1, 2-allenyl sulfoxide cyclization was reported in 2001 
by Mukai et al (Scheme 1.2.2).8 When alcohol 13 was subjected to the basic 
condition tBuOK/tBuOH, nucleophilic addition to allene followed by double bond 
migration occurred. Cyclic vinyl sulfoxides of different sizes, five to seven, were 
formed in good yields. However, eight member ring product cannot be obtained 
from the corresponding allenic sulfoxide.  
   
 
Scheme 1.2.2 Cyclic vinyl sulfoxide and sulfone formation via intramolecular Michael  
            addition of alcohol to allenic sulphoxide and allenic sulfone 
 Allenic sulfonyl derivatives 15 were also successfully transformed into oxacycle 
16 of different sizes (Scheme 1.2.2). Five membered to eight membered cyclic 
vinyl sulfones were all achieved in good yields. When a substituent group was 
attached to the other side of allene, substrates 17 and 18 were also smoothly 





 Several examples of cyclizations of allenic alcohols to prepare 2, 
5-dihydrofurans9 and furans10 have also been reported. Application of this 
approach to phosphorus-containing allenes can pave the way to phosphorylated 
furans and dihydrofurans. However, relatively little work have been performed on 
the synthesis and study of intramolecular cyclization of phosphorylated allenic 
carbinols. 
 In 2001, Brel reported an intramolecular oxa-Michael reaction of allenyl 
phosphonates (Scheme 1.2.3).11 The glycols 21a–i were easily prepared from 
 
Scheme 1.2.3 Intramolecular oxa-Michael reaction of allenyl phosphonates 
propargylic alcohols and obtained as a mixture of two diastereomers (31P NMR 
spectral data, in 1:1–1.4 ratio) resulting from the chirality of the allenic group. 
They are stable compounds and can be handled at ambient temperature. However, 
under basic conditions, they were cyclized to 2, 3-dihydrofurans via nucleophilic 
addition of the terminal alcohol to the central carbon atom of the allene system.  
Dihydrofurans 22a-f were obtained in good yields and high diastereoselectivities. 
Treated under acidic condition, compounds 22a-f were easily transformed into 





 Besides allenyl sulfoxides, allenyl sulfones and allenyl phosphonates, allenoates 
and 1, 2-allenic ketones are also good Michael acceptors. In 1994, Nagao found 
that treatment of diethyl (acetylamino)ethynylmalonate 24 with 1M KOH 
afforded trisubstituted oxazole 26 (Scheme 1.2.4) via a new mode of 5-endo 
cyclization of the resultant acetylaminoallenic ester intermediate 25.13 The 
intermediate was generated from hydrolysis of the ethyl ester followed by 
decarboxylation. Then the amide was enolized under basic condition and attack of 
the oxygen to the central carbon of the allenoate afforded the final oxazole 26. 
 
Scheme 1.2.4 Intramolecular Michael addition to allenotes  
In the same paper, an electrophilic Michael addition of carbon atom to allenyl 
ketone was also reported (Scheme 1.2.5).13 Allenyl aryl ketones 28a-g were easily 
prepared via the nucleophilic attack of propargylmagnesium bromide to amides 
27a-g. Under the treatment of a Lewis acid BF3-OEt2, 1, 2-allenyl ketones 28 
undergoes 5-endo mode cyclization to benzocycloketones 29 and 30. In this 
reaction, the presence of electron donating group on the aromatic moiety seems to 
be essential. The regioselectivity was controlled by the steric interaction between 







Scheme 1.2.5 Intramolecular Michael addition to allenic ketones, example 1 
 It was also found that allenyl aryl ketones are good substrates for the 
construction of medium sized rings. Compounds 32, 33, 34, containing six, seven, 
eight membered rings respectively, were all successfully achieved by tuning the 
length of the tether connecting the aryl group and the carbonyl group.14 The 
location of the C=C double bond in the products depended on the length of the 
tether. This reaction proceeded through a cationic intermediate 35 which was 
produced from the interaction of the Lewis acid with the carbonyl group. The 
cationic intermediate 35 would attack the aromatic ring as an electrophile to 




 In these reactions, the authors also found that the cyclization mode was 
determined by the substitution pattern of the aryl ring.15 For example, if one or 
both ortho-positions are occupied by a methoxy group like compound 36, the 
spiro-endo mode cyclization product 37 was obtained (Scheme 1.2.6). 
 
Scheme 1.2.6 Intramolecular Michael addition to allenic ketones, example 2 
 One limitation of the above reaction is that at least two methoxy groups are 
required on the phenyl ring. In 1998, Hashimi et al found that when 
4-methoxybenzyl-1,2-propadienyl ketone 38 was treated with 1 mol% of 
Hg(ClO4)2 in MeCN and water, the spiro-endo cyclization product 39 was formed 
in good yields (Scheme 1.2.7).16 They also found that the presence of water was 
important. The reason for the high efficiency of Hg(II) was believed to be the high 
coordination capability of Hg(II) ion to both the carbonyl oxygen and the terminal 
double bond.  
 




 For the intramolecular Michael reactions of allenes, both oxygen and carbon 
atoms have been involved as nucleophiles. However, no examples of aza-Michael 
reaction of allenes have been reported. This is probably due to the difficulty in 
obtaining such a substrate. Instead, intramolecular conjugate additions of nitrogen 
atom to allenes have been well developed. These reactions are usually 
electrophilic additions and catalyzed by metals, especially silver ion. Products of 
these reactions are usually pyrrolines,17 pyrroles,18 piperidines19 or pyridines,20 
which are all biologically important heterocycles (Scheme 1.2.8). 
 When the amino allenes 42a and 42b were treated with a catalytic amount of 
AgNO3 in acetone (25 °C, in the dark), 3-pyrrolines were obtained in good to 
excellent yields.21 The reaction readily formed both simple and annulated 
3-pyrrolines (43a and 43b). The procedure was very reliable and tolerant to a 
wide range of substitution patterns. As expected, the reaction showed little 






Scheme 1.2.8 Intramolecular conjugate addition of nitrogen to allenes  
 The piperidine structure has also been achieved via intramolecular conjugate 
addition of amine to allene.22 When the chiral allene 44 was treated with AgNO3, 
the piperidine 45 was obtained in good yield and the natural product 
(R)-(-)-Coniine was achieved in two more steps. The axial chirality of allene was 
fully transferred to the central chirality of the product. 
1.3 Intramolecular Diels-Alder reactions of allenes 
 Hydrogenation of one carbon-carbon double bond of allene will release an 
enthalpy of 41 kcal/mol. This is 12 kcal/mol greater than the enthalpy of 
hydrogenation of an ordinary alkene which is 29 kcal/mol. Accumulation of two 
carbon-carbon double bonds imparts extra reactivity to the allene, which makes it 
a remarkably active component participating in cycloaddition reactions. 
Cycloaddition reactions are categorized according to assembly modes, such as 
[m+n]-cycloaddition, where the variables m and n simply denote the number of 
atoms that each component contributes to the ring construction. Among these 
cycloaddition reactions, the [4+2] Diels-Alder reaction is the most important and 
useful in natural product synthesis.23 Because it leads to increasing molecular 
complexity, especially for intramolecular cyclization. As a result, the 
intramolecular Diels-Alder reaction of allene (either as dienophile or part of diene) 
has been drawing greater attention from organic chemists.  




 Allenes participate in the Diels-Alder type [4+2]-cycloaddition mostly as an 
electron-deficient dienophile. The LUMO energy level of an allene is lowered by 
the introduction of an electron-withdrawing unsaturated substituent. The largest 
LUMO coefficient is located on the central carbon (C2) and the next largest is on 
the substituted carbon (C1). Thus, Diels-Alder reaction of activated allenes takes 
place at the internal carbon-carbon double bond of the allene (Figure 1.1). 
  
Figure1.1 Allene models 
 When the allenic acid 46a and the allenic ester 46b were heated in refluxing 
toluene, intramolecular [4+2] cycloaddition between the diene and the internal 
double bond of allene ouccurred to give two bicyclic compounds with exo-isomer 
predominating (table 1.3.1).24 When a Lewis acid was used as a promoter, the 
[4+2] cycloaddition can occur at 0 oC in DCM with an inverse in stereoselectivity 
favouring the endo isomer. 
 
R R’ conditions Yield(%) endo:exo 
H Me Toluene, 110 oC 87 35:65 




H Me Et2AlCl, DCM, 0 
oC 65 87:13 
Me Et Et2AlCl, DCM, 0 
oC 49 87:13 
Table 1.3.1 Intramolecular [4+2] cycloaddition of allenic acid and ester 
 In the approach to synthesize Periplanone B developed by Cauwberghs and De 
Clercq in 1988, an allene-furan substrate 49 was synthesized as intramolecular 
Diels-Alder reaction substrate (Scheme 1.3.1).25 Upon treated in refluxing 
benzene, compound 49 underwent an IMDA reaction to afford the expected exo 
products 50 and 51 and an endo product (not identified). The transition states 
leading to the IMDA products were proposed and it was found that compound 50 
should be more thermally stable than compound 51 because of the equatorial 
isopropyl group. Under thermal dynamic control in refluxing mesitylene, the less 
stable compound 51 was found to cyclorevert to 50 and the ratio of 50:51 changed 
from 5:4 to 2:1. The IMDA product 50 was converted to 52 via a series of 
synthetic manipulations, which constituted a formal total synthesis of periplanone 
53. 
 A benzene ring can act as the diene in intramolecular [4+2] cycloaddition with 
an activated allene. Aryl allene carboxylates 54 gave tricyclic lactons 55 in 
moderate yields in xylene at reflux (Scheme 1.3.2).26 Allenyl amides were also 
explored in the intramolecular Diels-Alder reaction. Aromatic rings and furans 





Scheme 1.3.1 Intromolecular Diels-Alder reaction between allenic ketone and furan toward  
            the synthesis of Periplanone B 
 
 
Scheme 1.3.2 Intramolecular Diels-Alder reaction between allene and bezene 
 In Harwood’s investigation towards the synthesis of a morphinan skeleton 
(Scheme 1.3.3),27 the allenic amide 56 was designed as an intramolecular 
Diels-Alder substrate and it was found that on standing at room temperature, 56 
slowly underwent cycloaddition. However, the IMDA reaction was most 
conveniently carried out in refluxing toluene, in which the reaction will be 
finished in less than 2 h. Analysis of the crude material by NMR showed the 




assigned to be the desired diastereoisomer 57 on the basis of coupling constants 
and NOE difference studies. 
 
Scheme 1.3.3 Intramolecular Diels-Alder reaction of allenic amide, example 1 
 When compound 57 was treated with n-BuLi, the amino alcohol 58 was obtained 
and its structure was confirmed by X-ray crystallographic analysis, which further 
confirmed the structure and stereochemistry of compound 57. 
 
Scheme 1.3.4 Intramolecular Diels-Alder reaction of allenic amide, example 2 
 In 1982, Himbert developed allenyl carboxanilides 59, of which the aromatic 
rings acted as the diene to furnish the tricyclic lactams 60 in moderate to good 
yields (Scheme 1.3.4).28 The tendency to form tricyclic lactams 60 was attributed 
to the following factors: relatively easy formation of five-membered lactams, 
partial activation of the benzene ring by the amino group, increased 
energy-content of allene-systems relative to olefins, and comparatively high 
rigidity in the allene and carboxamide moieties.  
 A furyl-substituted sulfonylallene readily undergoes a [4+2] cycloaddition to 




refluxing benzene, the intramolecular Diels-Alder reaction proceeded smoothly to 
afford compound 62 in high yield.29 The rigid furyl diene was essential for the 
Diels-Alder reaction to occur. When the furan ring was changed to an open diene, 




Scheme 1.3.5 Intramolecular Diels-Alder reaction of sulfonyl allene 
 Nitrogen containing heterocycles are common and important constituents of a lot 
of natural products. Considering the efficiency of IMDA reactions of allene in 
constructing complex molecules, allenic amides and allenic carbonates have great 
potential in natural product synthesis. In 1986, Kanematsu and co-workers 
prepared alkynyl diene carbonate 65 and subjected it to Crabbe’ homologative 
allenylation. The allenic diene carbonate 66 was thus formed, and it underwent 
intramolecular Diels-Alder reaction spontaneously to afford the tetrahydroindole 
67. Upon dehydrogenation with DDQ, 67 was oxidized to indole 68. Differently 
substituted indoles can be synthesized via this sequence.30 The natural product 





Scheme 1.3.6 Total synthesis of hippadine via intramolecular Diels-Alder reaction of allenic  
            carbonate 
 Alkoxyallene is another type of allene that has been extensively studied. They 
are usually generated from base-catalyzed isomerisation of propargyl ether to 
allenyl ether. This kind of substrates usually generates furan rings after 
cycloaddition. Treatment of the propargyl ether 70 with tBuOK in refluxing 
tBuOH caused an intramolecular Diels-Alder reaction of the resulted intermediate 
allenyl ether 71 to afford the tricyclic compounds 72, which isomerized to 73 
spontaneously (Eq 1, Scheme 1.3.7).32 An asymmetric synthesis of benzofuran 
lactone 74 was achieved by an analogous procedure (Eq 2，Scheme 1.3.7).33 
Eq 1  




Scheme 1.3.7 Intramolecular Diels-Alder reaction of allenyl ether  
 An example of natural product synthesis involving allenyl ethers was reported by 
Kanematsu and Soejims in 1991(Scheme 1.3.8).34 They managed to synthesize 
euryfuran 80, which is a natural product possessing a synthetically challenging 
structure of 3,4-disubstituted furan ring, via a furan ring transfer reaction with the 
intramolecular Diels-Alder reaction of allenyl ether as the key step. Compound 75, 
when heated with potassium tert-butoxide, afforded the isomerisation product 76. 
This allene underwent a spontaneous intramolecular Diels-Alder reaction in 
tert-butanol at reflux to give compound 77. Deprotonation of α position of the 
furan oxygen initiated a ring opening of the oxybridge in 77 to give the furan 
transfer product 78. Repeating this process via the intermediate 79 led to the final 
target euryfuran 80. 
 
Scheme 1.3.8 Euryfuran synthesis via IMDA reaction of alkoxyallene 
 An asymmetric synthesis of the intermediate 84 of forskolin by Nagashima in 
1990 also employed intramolecular Diels-Alder reaction of allenyl ether (Scheme 




tert-butanol affords 83 as a single stereoisomer via the allenyl ether intermediate 
82. Further transformation of compound 83 led to the intermediate 84, which was 
readily transformed to forskolin. 
 
Scheme 1.3.9 Total synthesis of Forskoin via intramolecular Diels-Alder reaction of allenyl  
            ether 
 As a dienophile, an allene is able to cyclise not only with carbon dienes but also 
heterodienes. Both intermolecular36 and intramolecular hetero-Diels-Alder 
reactions of allenes have been developed.  
 An example of intramolecular hetero-Diels-Alder reaction of allene was reported 
by Boger in 1991during their work toward the total synthesis of trikentrin 87 
(Scheme 1.3.10).37 Treatment of 85 with acetic anhydride at 160 oC provided 
indole derivatives via a cascade reaction, N-acylation followed by [4+2] 
cycloaddition cascade followed by release of N2. Finally, deacetylation of 86 led 





Scheme 1.3.10 Total synthesis of tirkentrins via Hetero-Diels-Alder reaction of allene 
1.3.2 Intramolecular Diels-Alder reaction with allenes as dienes  
 Vinylallenes are commonly used as the diene component in Diels-Alder 
reactions, and thus they are ubiquitously used in natural product synthesis, 
especially their intramolecular Diels-Alder reaction. The natural compound 90 
Esperamicin A has been found to show great DNA binding and damaging 
properties which are traced to the bicyclic core structure equipped with an 
enediyne bridge. Vinylallene 88 was proposed by Schreiber and Kiessling to be a 
biogenetic intermediate for the synthesis of the skeleton of esperamicin A 
(Scheme 1.3.11).38 Although the proposed transformation (88–>89) was not really 
tested, the synthetic approach to esperamicin A was modeled in which an 
intramolecular Diels-Alder reaction was employed to synthesize the highly 
unsaturated bicyclic core of 90.  
 
Scheme 1.3.11 Proposal of the intramolecular-Diels-Alder reaction of vinylallene toward the   
             total synthesis of esperamicin A 
  Siloxyvinylallenes, which have been prepared by Reich et al in two ways, have 
proved to be good candidates for Diels-Alder reaction in which the 
siloxyvinylallenes act as the diene components.39 They are readily prepared by 




The vinylallene 91 was reported to be unstable and was subjected to a Lewis acid 
directly after preparation. It underwent intramolecular Diels-Alder reaction to 
afford the adduct 92 in 51% yield (Scheme 1.3.12). Both Lewis acid catalysis and 
thermal conditions proved to be successful for the Diels-Alder reaction. The 
cycloadduct 92 was subsequently converted to the natural product 93. 
 
Scheme 1.3.12 Intramolecular Diels-Alder reaction of vinylallene toward the total synthesis  
            of cis-Dehydrofukinone 
 (+)-Compactin 97 was synthesized by Keck and Kachensky via an 
intramolecular Diels-Alder reaction which used a vinylallene as the diene  
(Scheme 1.3.13).40 This work was done at a time when there was little literature 
precedent on the use of vinylallenes as dienes. Model study figured that the 
transition state for the Diels-Alder reaction of 94 would adopt a conformation to 
give only the exo cycloaddition product. Thus, the intramolecular Diels-Alder 
reaction perfectly constructed the bottom bicyclic structure. When compound 94 
was heated at 140 oC for one hour in toluene in the presence of BHT, it afforded 
the intermediate 95, which was immediately subjected to L-selectride to reduce 
the ketone to alcohol to avoid the formation of a conjugated enone. The resulting 
alcohol 96 was obtained as a 1:1 mixture of diastereomers in 84% yield. Although 
the two diastereomers could be separated, their stereochemistry was unknown at 




synthesis of (+)-compactin. One of these compounds matched the spectral data of 
97 exactly. 
 
Scheme 1.3.13 IMDA reaction of vinylallene toward the total synthesis of (+)-Compactin 
1.4 Summary 
 As an efficient and powerful tool for the construction of complex structures, 
especially regarding natural product synthesis, intramolecular cyclization 
reactions have been attracting more and more attention. As a class of reactive and 
interesting compounds, allenes have been well employed in different kinds of 
cyclizations. Excellent reactivity and selectivity have been achieved in these 
reactions. Most of the enantioselective examples are based on chiral auxiliaries or 
chiral starting materials. Some are developed under transition metal catalysis 
using a chiral ligand. However, there are few examples of organocatalyst 
catalyzed enantioselective intramolecular cyclization of allenes until now. The use 




catalytic enantioselective formation of allene towards natural product synthesis is 
quite attractive. The following chapters will describe our recent work on chiral 
allene formation followed by intramolecular Michael reaction and intramolecular 
Diels-Alder reaction. The first catalytic enantioselective total synthesis of 
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2.1 Different approaches for the preparation of piperidines and      
   lactams  
2.1.1 Piperidines and Lactams in natural products 
 Azacycles are important heterocyclic systems which are commonly found in 
natural products and valuable fine chemicals.1 In particular, functionalized 
piperidines and pyridines are present in a variety of pharmacologically active 
natural products including most of the alkaloids (Figure 2.1).2 The naturally 
occurring cinchonine alkaloids, which are known for their highly enantioselective 
catalytic activity in organic synthesis, have attracted increasing interest. These 
piperidine containing natural products are synthetically challenging, because they 
usually have several asymmetric centers present. Meanwhile, the most important 
step in the synthesis of these natural products is usually the ring-closing step to 
obtain the piperidine rings. A lot of attentions have been paid to the development 
of piperidine formation methods resulting in great advancements being made in 
this field. 
 
Figure 2.1 Piperidine or pyridine containing natural products 
2.1.2 Synthetic methods for piperidines and lactams  




(Scheme 2.1.1).2 Compound 102, the open chain form of compound 103, was 
prepared from 101 via enzymatic transamination. Asymmetric hydrogenation of 
compound 103 led to the natural alkaloid (+)-coniine 98. Hydroxylation of 
compound 103 led to hydroxyl imine 104, which was hydrogenated to afford the 
natural alkaloid 105 conhydrine. 
 
Scheme 2.1.1 Piperidine formation via amine-ketone condensation 
 Another method to prepare piperidine was developed in 2000 by Kunio 
Ogasawara (Scheme 2.1.2).3 This method employed ring closing metathesis (RCM) 
to form the heterocycle. When the N-protected secondary amine 106 was 
subjected to ring closing metathesis condition and then hydrogenation, the 
N-protected piperidine 107 was achieved in 89% yield over two steps, which is 
part of the natural product 100 (+)-febrifugine. 
 
Scheme 2.1.2 Piperidine formation via ring closing metathesis 
Intramolecular electrophilic addition of an amine to allene is another way to 
construct piperidine rings. Cha and co-workers reported one example in 1999 
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(Scheme 2.1.3).4 When the diastereomerically pure aminoallene 108 was 
subjected to a silver salt, silver nitrate, heterocyclization occurred via two 
transition states 109 and 110. The desired products quinolizidine 111 and 112, 
both possessing the desired E double bond geometry, were achieved in a ratio of 
7:1. From the proposed transition states, we can see that 109 is more favored than 
110 due to the steric repulsion between the silyl ether group and the allene tail. 
Compound 111 was successfully converted to the target natural products 
clavepictine A (113) and B (114). 
 
Scheme 2.1.3 Piperidine formation via intramolecular electrophilic addition of amine to 
            allene 
Trost B. M. and co-workers developed another route to synthesize piperidine in 
2000 (Scheme 2.1.4).5 A ruthenium catalyst (10%) and a co-catalyst CH3AlCl2  
were used. When allenyl amine 115 was subjected to a methyl vinyl ketone in the 




67% yield. It was found that both the Ru catalyst and the CH3AlCl2 co-catalyst are 
essential for the formation of the product. To achieve better yield, quenching with 
pyrrolidine was required, which is believed to dissociate the coordination between 
the product and the Ru catalyst. Both piperidines and pyrrolidines have been 
achieved using this method.  
 
Scheme 2.1.4 Piperidine formation via ruthenium catalysis  
In the same year, Lee E. and co-workers developed a radical process to 
synthesize such cyclic amines (Scheme 2.1.5).6 A protected secondary amine 118 
was chosen as the substrate for the radical cyclization. The radical precursor can 
be alkyl bromide or alkyl selenium. When compound 118 was subjected to the 
radical initiator AIBN and the hydride reductant, a mixture of diastereoisomers 
119 and 120 was achieved. The reaction tolerates both alkyl and aryl R 
substituents. Pyrrolidines can be formed as well. Compound 121 (-)-indolizidine 
223AB was synthesized employing two consecutive radical cyclization reactions 
of aminoacrylate substrates. 
Conversely, the cyclization of allenyl amides can occur under oxidative 
condition as developed in 2000 by Jonasson and co-workers (Scheme 2.1.6).7 
When the allenyl amide 122 was subjected to palladium catalyst and LiBr, an 
intermediate of π-allyl palladium complex 124 was formed. After an 
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intramolecular nucleophilic addition of the nitrogen to the π-allyl palladium 
system, the pyrrolidine product 123 was formed and Pd(II) was reduced to Pd(0), 
which was reoxidized by copper acetate.  
 
Scheme 2.1.5 Piperidine formation via radical cyclization 
 
Scheme 2.1.6 Pyrrolidine formation via oxidative cyclization 
In fact, this transformation can be achieved via cobalt mediated 
acylation-cyclization of allenes as well (Scheme 2.1.7).8 When compound 125 was 
subjected to the acetyltetracarbonylcobalt and the base diisopropylethylamine, the 





Scheme 2.1.7 Pyrrolidine formation via cobalt mediated cyclization  
Although first synthesized in 1907 by Staudinger, β- lactams were recognized in 
organic chemistry only until Fleming’s discovery of penicillin in 1929.9 The 
resulting recognition of the β- lactam moiety as the key pharmacophoric 
component of the penam antibiotics initiated a flurry of synthetic activity.10 Today, 
β-lactam rings are found in thousands of chiral compounds. Due to their high 
efficacy and safe toxicological profiles, penicillin and its derivatives are still the 
most commonly used antibiotics.  The asymmetric synthesis of β- lactams usually 
employs a [2+2] cycloaddition10 and one example is shown below (Scheme 2.1.8). 
 
Scheme 2.1.8 β–lactam synthesis via [2+2]-cycloaddition 
When an acid chloride 128 and an imine 129 were treated with the combination 
of a cinchona alkaloid derivative such as benzoylquinine (BQ) and a 
non-nucleophilic amine base, β- lactam products 130 were achieved in very high 
ee and dr. Varieties of acid chlorides were tolerated in this process.  
 [2+2]-cyclization can lead to β–lactam only, 5-membered and 6-membered 
lactams are formed via different methods. 
 In 2007, Che reported an intramolecular addition of β-ketoamide to unactivated 
alkenes under gold catalysis, which led to the formation of 5-membered lactams 
(Scheme 2.1.9).11 The reaction proceeded in toluene under mild condition. When 
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the β-ketoamide 131 was treated with the combination of a gold salt and a silver 
salt, the alkene was activated by the gold and attacked by the enolate leading to 
the formation of a 5-membered lactam 132. 
 
Scheme 2.1.9 5-membered lactam formation via gold catalys is 
Wei Ying and co-workers developed a convenient method for the synthesis of 
6-membered lactams in 2010 (Scheme 2.1.10).12 Deprotonation of the starting 
material 134 with a strong base NaH results in an aza-Michael reaction followed 
by an electrophilic ring opening of the cyclopropane. After a double bond shift, 
carbon anion 138 forms and condenses with an aldehyde to give the final product 
135. 
 





 In summary, a lot of natural products and synthetic compounds with medical 
potential are found containing heterocycles like piperidines and lactams. A great 
number of methods have been developed towards the formation of such systems. 
For the piperidine formation, either metal or harsh conditions were required. A 
mild organo-catalytic method will thus be much more attractive. Furthermore, the 
organo-catalytic enantioselective synthesis of six membered lactams is not 
available. We are pleased to report our work on piperidine and axial chiral lactam 
formation via organo-catalysis. 
2.2 Tandem isomerisation-aza-Michael reaction of alkynylamines 
and alkynylamides 
2.2.1 Synthesis of alkynyl amines and chiral bicyclic guanidine catalyst.  
 Alkynyl amines 141a-141c were synthesized as outlined in scheme 2.2.1. 
Standard amide formation protocol between different anilines and pent-4-ynoic 
acid afforded different alkynyl amides 139 in around 70% yield, which were then 
 
Scheme 2.2.1 Alkynyl amine synthesis 
reduced to alkynyl amines 140 with LiAlH4. After a well-established coupling 
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between the alkyne moiety and diazo compounds,13 the desired compounds 
141a-141c were obtained. 
Treatment of alkynyl amines 141a-c with a brønsted base TBD formed the 
products 142a-c in good yields (Scheme 2.2.2). Slightly long reaction time (24 
hours) was required to ensure that the reaction proceeded to completion as the 
products 142a-c were non-separable from their corresponding alkynyl-amines 
141a-c.  
 
Scheme 2.2.2 Brønsted-base catalyzed tandem isomerization-aza-Michael reaction of  
            alkynyl-amines 141. 
a
 Isolated yield 
Since the reaction is base catalyzed and the starting material itself is a base, we 
doubt whether self-catalyzed reaction is possible. For better understanding of  
 
Scheme 2.2.3 Proposed mechanism for tandem isomerization-aza-Michael reaction of 141 




one day without the presence of the base, TBD. The starting material was fully 
recovered and no other product was obtained. Hence, the self-catalyzed reaction 
mechanism was excluded. Therefore, we believe that the tandem isomerization- 
aza-Michael reaction goes through the proposed pathway in Scheme 2.2.3. 
 Since we have been interested in the brønsted base, bicyclic chiral guanidine 149, 
catalyzed asymmetric transformations, we expected that alkynyl amine 141c may 
afford 142c with axial chirality when the reaction was catalyzed by our chiral 
guanidine. The chirality was generated from the restricted rotation of the C-N 
bond connecting the piperidine ring and the phenyl ring.  
 The chiral bicyclic guanidine was prepared by the well-established procedure 
published by our lab.14 N-Tosyl aziridine 146 was readily prepared from its 
 
Scheme 2.2.4 Synthesis of the chiral bicyclic guanidine 149 
corresponding commercially available α-amino alcohol 145 via a two-step process. 
Triamine unit 147 was easily obtained by treating N-tosyl aziridine 146 in MeOH 
saturated with NH3 gas in a sealed vessel. After removing the solvent, the residue 
was dissolved in MeCN and refluxed for 3 days. The subsequent removal of tosyl 
groups was conducted in liquid ammonia in the presence of sodium. After the 
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final cyclization step, the triamine intermediate was cyclized to give the chiral 
bicyclic guanidine149 and basified with 5 M KOH aqueous solution or solid 
K2CO3 (Scheme 2.2.4). 
 The alkynyl amine 141c was treated with bicyclic guanidine 149 in different 
solvents and the results are summarized in Table 2.1. The reaction proceeded 
fastest in DCM and reached completion in 24 hous, however, no enantioselectivity 
was observed (Entry 1). Toluene gave 0% ee as well and a non-complete reaction 
(Entry 2). Pleasingly, hexane gave 7 % ee and the best ee achieved was 27% in 
THF. However, the starting material cannot be completely consumed in hexane 
and THF even after 3 days. Since the starting material and the product cannot be 
separated and the reaction cannot proceed to completion, no further study was 
conducted. 
Table 2.1 Solvent effect on asymmetric tandem isomerization-aza-Michael reaction of 
        alkynyl amine 141c 
 





1 DCM 24 h 100 0 
2 Toluene 24 h 70 0 
3 Hexane 32 h 50 7 






 determined by HPLC 
2.2.2 Bicyclic guanidine catalyzed enantioselective tandem isomerisation- 




 Based on our discovery of the tandem isomerization-aza-Michael reaction, 
especially the asymmetric reaction performed on alkynyl amine141C, We were 
keen to achieve a high enantioselectivity by tuning the substrates. We have 
demonstrated that 3-Alkynoates bearing a tButyl ester will afford highly 
enantioselective allenes when treated with bicyclic guanidine. It is believed that 
the axial chirality of the piperidine 142c was transferred from the chiral allene 
which was generated in situ. The poor ee of 142c is probably due to the low 
energy level that is required for the rotation of the C-N bond. We expected that the 
energy level could be increased by adding hindering substituents. Thus we 
synthesized the alkynyl amide 150 from 139b by alkyne and diazo compound 
coupling (Scheme 2.2.5). We expected that the extra carbonyl group would help to 
restrict the rotation. 
 
Scheme 2.2.5 Synthesis of alkynyl amide 150 
 The alkynyl amide 150 was then treated with bicyclic guanidine 149 in different 
solvents. Two cyclized products were detected, which were assigned as 151 and 
152 by 1H NMR. The ratio between 151 and 152 on TLC was about 4:1. 
Subsequently, by passing the reaction mixture through a silica gel column slowly, 
cyclic compound 151 can be fully converted to lactam 152. 
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 Optimization results are summarized in Table 2.2. Similarly, the fastest reaction 
was observed in DCM, full conversion was observed after stirring at rt for 4 days 
as indicated by TLC analysis. However, only moderate yield was obtained after 
separated by column chromatography with 60% ee (Entry 1). The best 
enantioselectivity was obtained in ether type solvents (Entry 3 and 5). Different 
ethers were tested as well but THF still gave the best result (Entry 5, 8 and 9). 
With THF as solvent, different concentrations were tested and it was found that 
dilution led to very slow reaction time (Entry 6) while concentrated reaction 
afforded much lower ee (Entry 7). 
Table 2.2 Bicyclic guanidine catalyzed enantioselective tandem isomerization-aza-Michael  
         Reaction  
 





1 DCM 0.1 4 68 60 
2 Toluene 0.1 3 60 81 
3 Ether 0.1 2 75 85 
4 Hexane 0.1 2 74 65 
5 THF 0.1 3 67 89 
6 THF 0.01 6 <10 nd 




8 TBDME 0.1 4 70 72 
9 Phenylmethyl ether 0.1 4 60 67 
a
 isolated yield 
b
 determined by HPLC 
 Having achieved the axial chiral lactam 152 with high enantiomeric purity, we 
encountered some difficulty with the establishment of its absolute configuration. 
Difficulty in obtaining single crystals for 152, together with the lack of heavy 
atoms in 152 impeded absolute configuration determination via single crystal 
X-ray diffraction.15 As a result, we had to derive the absolute configuration via 
theoretical approaches. Reliable specific optical rotation can be calculated from 
density functional theory (DFT) by considering thermally accessible 
conformations and with judicious choice of basis set and functional coupled with 
solvation model to account for solvent effects.16 The specific optical rotation for 
152-Sa configuration calculated is -57.8, which agrees well with the -64.1 
obtained experimentally. 
 In addition, we have investigated the mechanism via DFT calculation. The 
enantioselective step is postulated to be the intramolecular Michael reaction. The 
activation barriers for the relevant pathways are given in figure 2.2. Based on this 
mechanism, the formation of Sa product is predicted to be more favourable than 
the Ra product. The Gibbs free energy of activation difference (∆G
‡) of the 
pathways leading to the Sa lactam is 3.4 kcal/mol lower in Gibb free energy than 
the pathway leading to the Ra lactam, which is consistent with the high ee 





Figure 2.2: Enantioselectivity step (Gibbs free energy difference given in 
kcal/mol)  
 As an interesting axial chiral lactam, compound 152 is also a potentially useful 
intermediate in organic synthesis. It will be extremely interesting if different ring 
sized lactams, especially larger rings, can be achieved with similar axial chirality. 
Different alkynyl amides and carbonates that might lead to larger rings were 




 eq 1 
eq 2 
           eq 3 
eq 4 




Scheme 2.2.6 Synthetic schemes to different alkynyl amides and carbonates 
 However, efforts to prepare atropisomeric lactams with different ring sizes were 
not too successful. Upon exposure to bicyclic guanidine 149, alkynes 153-157 
were unable to complete the intramolecular Michael reactions and provided  the 
corresponding enantio-enriched allenes, whose absolute configurations were 
determined by the Lowe-Brewster rule (Scheme 2.2.7) .17 
 




 The observation of allenes when 153, 154, 155, 156 and 157 were used as 
reactants suggests that the formation of 152 from 150 proceeds via an allene 
intermediate.  
2.3 Summary 
 In conclusion, we have found that a Brønsted-base catalyzed tandem 
isomerization-aza-Michael reaction can be used to form useful heterocycles under 
mild conditions. This efficient method was applied to the synthesis of 
functionalized piperidine with good yields. Enantioselective tandem 
isomerization-aza-Michael reaction of alkynyl-amide led to an axially chiral 
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3.1 Introduction to the Synthesis of alpha-Yohimbine 
 Alpha-Yohimbine, also known as isoyohimbine, rauwolscine, and orynanthidine, 
is an alkaloid found in various species within the genera Rauwolfia and 
Pausinystalia (formerly known as Corynanthe).1 It is a stereoisomer of yohimbine. 
Alpha-Yohimbine is a central nervous system stimulant, a local anesthetic and a 
vague aphrodisiac.1 It acts predominantly as a α2-adrenergic receptor antagonist.
2 It 
has also been shown to function as a 5-HT1A receptor partial agonist and 5-HT2A, 
5-HT2B receptor antagonist.
3 Due to its important pharmacological effect and 
synthetically challenging structure, chemists have paid considerable attention to the 
synthesis of alpha-yohimbine. However, only limited numbers of successful 
synthetic routes have been developed until now. There is no enantioselective total 
synthesis available before this report.  
During nineteen seventies, Tökel and co-workers did a lot of study on the 
synthesis of yohimbines.4 During their work toward the total synthesis of 
alloyohimbines, they found that alpha-yohimbine 170 was formed via 
epimerization at C3 (Scheme 3.1.1).4c The synthesis started with the cyclization of 
N-formyl tryptamine 160 using POCl3 under thermal condition, which delivered 
compound 161 containing the A, B, C rings of the pentacyclic structure in 
yohimbine bases. A Mannich reaction followed by an aza-Michael reaction 




substituents for further manipulation, affording the compound 163. Upon 
condensation with diethyl cyanomethylphosphonate 164, a cyano group was 
introduced to form the nitrile ester 165. Pd/C catalyzed hydrogenation afforded 
two products 166a and 166b. The major product 166a is a trans isomer which was 
transformed into yohimbine. The minor product 166b is a cis isomer which is a 
potential candidate for allo-type yohimbines. Treatment of 166b with a strong 
base, potassium tert-butyloxide in DMSO, afforded the pentacyclic compound 
167 which contained nitrile and ketone moieties. Reduction of the ketone using 
sodium boron hydride afforded two alcohols 168a and 168b in a ratio of 2:3. 
Scheme 3.1.1 Total synthesis of alpha-yohimbine, route 1 




As a final step in the synthesis, the nitrile group was converted to methyl ester by 
first converting the nitrile in 168b to acid amide using hydrogen peroxide in 
alkaline methanol. Subsequent refluxing with aqueous HCl afforded the free acid, 
which was converted to methyl ester using diazomethane to afford the 
3-epi-alpha-yohimbine 169 and certain amount of alpha-yohimbine 170. The 
alpha-yohimbine was believed to have formed via the epimerization at C3 during 
hydrolysis with aqueous HCl. Since the alpha-yohimbine was formed from a 
minor isomer of the hydrogenation step, the yield was extremely low.  
Following the work above, the same group developed a new route that gave 
better yield for the synthesis of alloyohimbines (Scheme 3.1.2).4d The readily 
available compound 163 was condensed with methyl cyanoacetate 171 in 
triethylammonium acetate in the presence of phosphrous pentaoxide to form 
compound 172. It was found that an epimerization at C20 occurred. Reduction 
with sodium boron hydride in MeOH at 0 oC afforded the compound 173, which 
was then converted to diacid 174 by hydrolysis and acidification. Decarboxylation 
via boiling in DMF and esterification with methanolic HCl afforded the diester 
175. The condensation between the two ester groups required highly dry condition 
and as expected yielded 176 (36%) and 177 (30%) in similar yields. Reduction of 
the ketone 177 with sodium boron hydride afforded a mixture of alloyohimbines, 
but alpha-yohimbine 170 was obtained in only 6% yield. 




Scheme 3.1.2 Total synthesis of alpha-yohimbine, route 2 
route 1, alpha-yohimbine is still produced as a minor product and poor selectivity 
is still obtained in several steps. These reasons result in the extremely low overall 
yield for alpha-yohimbine. 
 Another contribution was made by Wenkert E. et al in 1979 (Scheme 3.1.3).5 
They constructed a structure of indoloquinolizidine with necessary functional 
groups in a quite efficient way. Condensation between nicotinaldehyde and 
malonic acid under piperidine catalysis afforded an unsaturated acid which was 
transformed into ester 180 with acidic MeOH. Alkylation of the ester with 
tryptophyl bromide yielded the desired pyridinium salt 181, which was attacked 
by dimethyl sodiomalonate at the γ-position to afford the tetracycle 182. Since 
only two ester groups were required, iodide- induced demethylation was 





Scheme 3.1.3 Total synthesis of alpha-yohimbine, route 3 
performed on 182, and the diester 183 was obtained in good yield. Reduction of 
the diene moiety was done with sodium boron hydride which afforded a mixture 
of 184, 185 and 186. Hydrogenation converted 184 to 185 and 186 in almost the 
same yields. Direct hydrogenation of 183 would similarly lead to formation of 
185 and 186, however, the yield for 186 is considerably low. Then compound 186 
was epimerized via mercury acetate oxidation and NaBH4 reduction to 175, which 
had been transformed to alpha-yohimbine in Scheme 3.1.2. 
Until date, Martin S. F. and coworkers developed the most efficient method 
toward the synthesis of alpha-yohimbine.6 They employed an intramolecular- 




C was formed via mercury catalyzed oxidative cyclization. 
Scheme 3.1.4 Total synthesis of alpha-yohimbine, route 4 
As shown in Scheme 3.1.4, the amide 192 required for intramolecular-Diels- 
Alder reaction was conveniently prepared in six direct steps. Subsequent 
thermolysis of 192 in xylene at reflux proceeded smoothly to afford the 
cycloadduct 193. The next stage is to set the functionality on the ring E. 
Regioselective epoxidation and subsequent epoxide opening installed the required 




alcohol that was present in the final product (193-195). The MOM protected 
alcohol was then deprotected and oxidized. The following esterification afforded 
the methyl ester group that was present in alpha-yohimbine (196-197). Under H2 
in the presence of Pd(OH)2, the benzyl protecting was removed together with the 
side chain of ester which was used as a nucleophile to open the epoxide. With the 
free amine, the indole moiety was installed by alkylation to afford compound 200. 
Finally, an oxidative cyclization and reduction sequence led to the final product 
alpha-yohimbine 170. 
 In conclusion, as a pharmacologically and synthetically important natural 
compound, alpha-yohimbine has attracted considerable attention of chemists. 
Most of the present synthetic routes are developed during the synthesis of other 
yohimbines and the overall yields are quite low. The route by Martin S. F. was the 
most direct completing the synthesis in 19 steps, which is considerably reasonable.  
There has been no reports on enantioselective synthesis of alpha-yohimbine. We 
would like to introduce our work on bicyclic guanidine catalyzed 
intramolecular-Diels-Alder reaction of alkynoates: the first enantioselective 
synthesis of alpha-yohimbine, which was achieved via a shorter and more 
efficient route. 
3.2 Tandem isomerisation intromolecular-Diels-Alder (IMDA) 
reaction of alkynoates: total synthesis of (+)-alpha-yohimbine 




intramolecular-aza-Michael reaction of alkynoates (Eq 1, Scheme 3.2.1). We were 
interested to develop an intramolecular-Diels-Alder reaction using the in-situ 
generated chiral allenes, which will produce hydroisoquinoline derivatives (Eq 2, 
Scheme 3.2.1). 
 
Scheme 3.2.1 Initial plan for the construction of hydroisoquinoline derivative - core   
            structure of yohimbines 
3.2.1 Synthesis of intramolecular-Diels-Alder (IMDA) reaction substrates 
First, some Diels-Alder substrates were synthesized with open dienes (Scheme 
3.2.2). Alkynyl amide 201 was then synthesized via amide coupling between (2E, 
4E)-hexa-2, 4-dienoic acid and propargyl amine followed by coupling between 
terminal alkyne and diazo compound. Alkynyl amide 202 was synthesized in 
similar way as previously mentioned. The two compounds were both obtained 
together with small amount of allenes. Since the amide and allene are inseperable, 
they were not characterized and were treated with TBD in DCM together. 
However, no cyclization occurred and only allene was obtained. Further thermal 
treatment of the allene in toluene under reflux did not result in any reaction.  





Scheme 3.2.2 Synthesis of IMDA substrates containing opening diene 
 As such, we begin to focus on alkynyl amides with cyclic diene moiety. 
Substrates with a furan ring and an alkyne can be easily obtained by the protocol 
as outlined in Scheme 3.2.3. 
 
Scheme 3.2.3 Synthesis of IMDA substrates containing cyclic diene  
The synthesis begins with an SN2 substitution between furfuryl amine and 
propargyl bromide in the presence of 1 eq lithium hydroxide. To minimize the 




However, compound 205 was still formed in 10% yield. The desired product 206 
was obtained in 80% yield. Then the secondary amine 206 was protected with an 
amine protecting group (Table 3.1), such as Pivaloyl. Majority of this protecting 
step uses the condition as described in Scheme 3.2.3. However, there are a few 
substrates, which employ conditions that are different and can be found in chapter 
4. Amides 207 are obtained in considerably good yields. Finally coupling between 
terminal alkyne and diazo compounds afforded the desired IMDA subsrates 208. 
In our previous cases,7 the coupling step always produced some allene as 
inseperable by-products. However, we did not observe any allene and isolated 
only the intramolecular-Diels-Alder cycladdition products. 
3.2.2 Optimization study of the intramolecular-Diels-Alder reaction 
These new substrates were subjected to our catalyst, bicyclic guanidine. 
Pleasingly, guanidine was found to promote the intramolecular-Diels-Alder 
(IMDA) reaction and the IMDA products were obtained in good yields, moderate 
dr, and moderate to good ee.  
During our initial study, we screened different solvents for this IMDA reaction 
using 208a as a model substrate (Table 3.1). The reaction is generally a bit slow. 
Chlorinated solvent (DCM) led to very low enantioselectivity (Entry 3) although 
the reaction was a bit faster. Toluene, hexane and ether type solvents (THF and 
diethyl ether) resulted in ees of same level. However, all of the ees were only 
moderate. From prior experience, we postulated that the size of the ester group 




could affect the enantioselectivity thus we changed the ethyl ester to a tert-Butyl 
ester as shown in Table 3.2. 
Table 3.1 Solvent effect on IMDA reaction 
 













(208aa %/208ab %) 
1 THF 2 100% 3:1 55%/56% 
2 Toluene 2 100% 3:1 59%/59% 
3 DCM 2 100% 7:3 38%/38% 
4 Et2O 4 90% 4:1 60%/63% 
5 Hexane 4 90% 4:1 60%/60% 
Reactions were run on a 0.01 mmol scale with 10 mol% bicyclic guanidine in 0.5 ml solvent. 
a





 determined by crude 
1
H NMR. 
c determined by chiral HPLC analysis. 
 The ee was increased by about 20% in Hexane (Entry 5, Table 3.1 vs Entry 6, 
Table 3.2) and diethyl ether (Entry 4, Table 3.1 vs Entry 7, Table 3.2) giving the 
best ee so far. Other ether-type solvents were screened as well, and TBME gave 
similar enantioselectivity (Entry 10). Preliminary screening with various 
concentrations indicated that a change in concentration would lead to a drop in ee 
(Entry 10-12). We also attempted to lower the temperature but the reaction 
became extremely slow and the ee was not increased. Different catalyst loadings 
were also screened but the enantioselectivitives were not improved as well. 
Finally, we decided to choose hexane as reaction solvent because it is cheap and 
not as volatile as diethyl ether. Substrates bearing different protecting groups were  




















(208ba %/208bb %) 
1 THF 0.02 4 80% 3:1 68/70 
2 EA  0.02 3 80% 4.5:1 73/75 
3 MeCN 0.02 2 100% 1.7:1 21/21 
4 Tol 0.02 2 80% 4:1 72/75 
5 DCM 0.02 2 100% 4:1 46/50 
6 Hexane 0.02 4 80% 4:1 79/80 
7 Ether 0.02 4 90% 4.5:1 77 /78 
8  0.02 3 100% 7:1 60/62 
9 PhOMe  0.02 3 90% 7:1 71/73 
10 TBME 0.02 4 85% 4:1 79 /80 
11 TBME 0.01 4 90% 7:3 60/35 
12 TBME 0.005 4 50% 4:1 72/62 
13 nBu2O
d 0.02 7 0 nd nd 
14 1,4-dioxane
d 0.02 7 0 nd nd 
Reactions were run on a 0.01 mmol scale with 10 mol% bicyclic guanidine in 0.5 ml solvent. 
a 









determined by HPLC analysis. 
d
 not determined 
subjected to the optimal condition which employs hexane as solvent under room 
temperature condition with a concentration of 0.02M and 10 mol% catalyst 
loading. 
 Different N protecting groups led to slightly different reaction rates and ees 
(Entry 2-8). The best result was achieved with the Boc protecting group, when a 
triethyl methyl type ester was employed (Entry 9). When the nitrogen atom was 
protected using tosyl group, the reaction rate increases probably due to the strong 
electron withdrawing ability of sulfonyl group, but the ee obtained was bad. 
Majority of the two diastereoisomers can be separated via chromatography on 
silica gel. The IMDA products of 208e and 208g can be obtained only as 




diastereoisomer mixtures. We confirmed the IMDA products 208ba and 208ca by 
X-ray analysis (Scheme 3.2.3) and 1H NMR and 13C NMR analysis. We failed to 
obtain any X-ray structure of the cis IMDA product, instead we obtained the X-ray 
structure of the hydrogenation product of compound 208bb, which can also help 
to determine the structure of the cis compound.  
Table 3.3 Intramolecular-Diels-Alder (IMDA) reaction of 208 
 









1 208a(Piv, Et) 4 87.5 88.5 3:1 60/60 
2 208b(Piv, tBu) 4 80 75 4:1 83/83 
3 208c(Boc, tBu) 7 84 91 3.3:1 79/77 
4 208d(Cbz, tBu) 7 76 89 4:1 77/77 
5 208e(Ts, tBu)
e
 3 100 80 2:1 76.5/80 
6 208f(4-bromo 
Benzoyl, tBu ) 





7 77 72 4:1 68/69 
8 208h(Boc, CEt3) 8 85.3 80 4:1 87/87.5 
9 208i (Piv, CEt3) 5 86% 80 3:1 87/88 
Reactions were run on a 0.2 mmol scale with 10 mol% bicyclic guanidine in 10 ml hexane at room 
temperature. 
a
 based on recovered starting material. 
b
 isolated yield (10xa+10xb) based on 
conversion. 
c




 determined by HPLC analysis. 
e
 the reaction was run in  
THF due to low solubility. 
 Other DA products were confirmed by comparing the 1H, 13C NMR data with 
that of 10ba and 10bb. Due to the lack of heavy atoms in the molecule, the 
absolute configurations of products 10ca and 10cb were determined via DFT 







       
Hydrogenation product of compound 208bb 
  
Scheme 3.2.4 X-ray structures of the compounds 208ba, 208ca and the X-ray structure of the   
            hydrogenation product of compound 208bb. 
3.2.3 Enantioselective total synthesis of (+)-alpha-yohimbine 
To achieve the synthesis of the natural product alpha-yohimbine 170, we 
designed the substrate 208g. The indole moiety was installed as a protecting group 
to facilitate the IMDA reaction. The IMDA products contain all the elements that 
are required in alpha-yohimbine. The natural product synthesis can be completed 
in a few steps with first cyclization to form the ring C, followed by amide 
reduction, olefin hydrogenation and transesterification. We proceeded to attempt 
the total synthesis with 208ga according to the route as discussed (Scheme 3.2.5). 







Scheme 3.2.5 Intramolecular-Diels-Alder reaction of substrate 208g and manipulation on the    
           IMDA product 208ga 
We first attempted to cyclise the IMDA product 208ga via oxidative cyclization 
which has been used to form the ring C by the oxidation of tertiary amine to 
iminium.6 However, the amide oxidation did not work. As such, we decided to 
reduce the amide instead. IMDA products are generally not stable probably due to 
the double bonds. Hydrogenation of 208ga gave 210 in good yield. The amide 
210 was subjected to kinds of conditions for tertiary amide reduction, like borane, 
sodium boron hydride in the presence of Lewis acid, Hantzsch ester in the 
presence of Tf2O, Silane in the presence of zinc acetate.  But all of these 
conditions did not work. Compound 210 was either recovered or decomposed. 
The strong reducing reagents LiAlH4 did reduce the amide to amine, however, the 




in oxidation state of the compound made the route not appealing. 
Manipulation on other IMDA products was then planed. Deprotection of the 
nitrogen atom followed by alkylation or reductive amination should install the 
indole moiety without an oxidation state change. Compound 208ca was selected 
to be the desired starting point due to the easy removal of Boc group as well as its 
high ee (Scheme 3.2.6). 
 
Scheme 3.2.6 Attempt on the total synthesis starting with compound 208ca 
IMDA product 208ca was hydrogenated to afford two compounds 211 and 212 
in a ratio of 1:4 in quantitative yield. Then the main product 212 was treated with 
TFA in DCM to remove the Boc protecting group. Temperature and amount of 
TFA have been screened. It was found that the reaction in a mixture of TFA and 
DCM (volume ratio of 1:4) at 0 oC for 10 minutes, gave the free amine 213 in the 
best yield (80%). Less TFA resulted in a longer reaction time. Longer reaction 




time and high temperature resulted in the reaction of tert-butyl ester with TFA. 
The tert-butyl ester was changed to carboxylic acid resulting in a lower yield of 
the amine.  
Secondary amine 213 was not purified and used directly after quenching and 
extraction. Alkylation of the amine with tryptophyl bromide in DMF or MeCN in 
the presence of K2CO3, afforded compound 214 in quite low yield (around 20%). 
The reason is probably the oxa-bridge reduced the nucleophilicity of the nitrogen 
atom. Then reductive amination using 2-(1-H-indol-3-yl)-acetaldehyde was 
carried out. The condition was reported by Eric. N. Jacobsen during their 
synthesis of yohimbine.9 Compound 214 was obtained in 60% yield. The 
transesterification proceeded smoothly in the presence of 1 eq of CSA in refluxing 
MeOH and the methyl ester 215 was achieved in 80% yield. Then the oxidative 
cyclization using mercury acetate followed by NaBH4 reduction was employed to 
form the ring C. Two products 216 and 217 were achieved in same yield (30%). 
Compound 217 was the desired product.  
In order to attain the hydroxyl group at C-18, the oxa-bridge has to be opened.  
Initially Lewis acid, such as ZrCl4, and BF3 were attempted, but these were not 
strong enough, only the starting material 217 was recovered. Stronger Lewis acid 
BCl3 led to a messy reaction at -20 
oC, and no product could be isolated.  The 
temperature was lowered to -78 oC but there was no reaction. Brønsted acids such 




work as well and no reaction was observed. Finally, it was found that 
trifluoromethanesulfonic acid could promote the ring opening with DCM as 
solvent. On closer analysis of the structure with NMR (1H, 13C, COSY, HMQC, 
NOESY), we confirmed that the compound is 218. However, the hydroxyl group 
was formed at C20 instead of C17. This result can be explained by the 
neighboring carbonyl stabilization of the carbon cation intermediate 219 (scheme 
3.2.7). 
 
Scheme 3.2.7 Ring opening of compound 217 with triflic acid 
So far, we observed that in acid catalysis, the carbon cation prefers to form at 
C-17 rather than C-20 and alpha-yohimbine was not possible to achieve via this 
route. As such, we decided to take a different approach and open the oxabicyclic 
ring with a nucleophile before the double bonds were reduced. 
Different conditions have been screened, however, in most results either no 
reaction was observed or the starting material was decomposed and no isolation of 
product was possible (Entry 1-8, Table 3.4). The palladium-catalyzed 
hydrostannation of olefin led to 50% yield of 220, which would afford a tertiary 
alcohol instead of the desired secondary alcohol after destannation (Entry 9). 
Finally, the desired product 221 was obtained via nickel catalyzed reductive 
oxabicyclic ring opening with DIBAL-H as hydride source (Entry 10). Due to the 




low yield obtained, an optimization was done. 




 condition time result 
1
10
 2 eq ZrCl4, 0.1 M in DCM 2 d  Decomposition 
2 TiCl4, DCM, -78 
o
C 1 hr Decomposition 
3 2 eq SmI2, THF 24 hr No reaction  
4 2 eq Red-Al, toluene, rt  24 hr No reaction  
5
11
 2 eq PhSH, 2 eq BF3-Et2O, DCM, rt 24 hr Decomposition 
6 2 eq PhSH, 2 eq Et3N, DCM, rt 24 hr No reaction  
7 LiNH2, -78 
o
C 1 hr Decomposition 
8
12
 LTBAH, Et3B, THP 24 hr No reaction  
9
13
 20 wt% Pd(OH)2, 1.5 eq Bu3SnH, THF 2 hr 
 
220, 50% y ield  
10
14
 0.1 eq Ni(COD)2, 0.4 eq PPh3, 1.2 eq DIBAL-H in 
hexane, rt  
2 hr 
 
221, 11% yield  
Reaction details see corresponding literatures. 
a
 Corresponding literatures 
The reaction using Ni(COD)2 and DIBAL-H system was very fast. Catalytic 
amount of Ni(COD)2 led to quite low yield (Entry 1-2, Table 3.5). Increase in the 
catalyst loading gave better yield (Entry 4). Excess of DIBAL-H would decrease 
the yield because of the side reaction of ester reduction (Entry 3). Actually, side 
product from olefin hydroalumination was also detected via LCMS. The best yield 
(50%) was achieved when 1 eq of Ni(COD)2, 4 eq of PPh3 and 1.3 eq of 




-78 oC did not improve the result (Entry 6). 
Table 3.5 Optimizat ion of reductive oxab icyclic ring opening of IMDA product  208ca 





1 0.1 eq  0.4 eq  1.2 eq in heptane rt 70% 11% 
2 0.3 eq  1.2 eq  1.2 eq in heptane rt 90% 30% 
3 0.3 eq  1.2 eq  2.3 eq in heptane rt 100% 24% 
4 1 eq  4 eq  1.1 eq in heptane rt 80% 35% 
5 1 eq  4 eq  1.3 eq in heptane -78 
o
C-rt  80% 40% 
6 1 eq  4 eq  1.3 eq in toluene -78 
o
C-rt  80% 45% 
7 1 eq  4 eq  1.3 eq in toluene 0 
o
C 90% 50% 
8 1 eq  4 eq  1.5 eq in toluene -78 
o
C-rt  90% 42% 
9 1 eq  4 eq  2.0 eq in toluene -78 
o
C-rt  100% 20% 
    Reaction details see chapter 7. 
a 
based on TLC analysis 
b
 isolated yield. 
Compound 221 is found to be unstable as after standing at rt or even -30 oC for 
overnight, new spots were observed on TLC. Direct hydrogenation of compound 
221 led to messy reaction. Thus, the alcohol was protected with acetyl group 
using 1.5 eq of acetic anhydride with DMAP as catalyst in the presence of 1.5 eq 
of Et3N (Scheme 3.2.8). The O-protected product 222 was obtained in 80% yield 
with no ee change. 
 
Scheme 3.2.8 Protection of alcohol group in compound 221 
Having achieved compound 222, we aimed to reduce the two double bonds.  It 
was speculated that the bulky tert-butyl ester group would help to form the 
desired product 223 during heterogeneous hydrogenation. Unfortunately, only a 




mixture of two diastereoisomers that could not be separated was obtained and the 
stereochemistry of the products could not be determined at this moment. To 
increase the yield and the dr, an optimization was also performed (Table 3.6). 
Table 3.6 Optimizat ion of hydrogenation of compound  222 
 





1 10%Pd/C 30 wt% rt 2 d  70% 4:1 
2 10%Pd/C 100 wt% rt 2 d  60% 4:1 
3 20%Pd(OH)2 50 wt% rt 2 d  60% 3:1 
4 10%Pt/C 100 wt% rt 2 d  50% 8:1 
5 10%Pt/C 200 wt% rt 2 d  30% 5:1 
6 10%Pt/C 50 wt% rt 3 d  50% 8:1 
7 10%Pt/C 50 wt% 70 
0
C 3 d  10% 8:1 
a
 based on crude nmr analysis and ESI mass analysis 
b
 based on crude nmr analysis  
By ESI mass analysis, it was found that there was always a monohydrogenated 
product 225, which could not be isolated and its double bond could not be located. 
By crude 1H NMR analysis, its ratio could be determined. The stereochemistry of 
compounds 223 and 224 cannot be determined at this stage but the 
stereochemistry of the major product 223 was later determined. A brief catalyst 
screening indicated that Pt/C is better than Pd/C and Pd(OH)2/C in the perspective 
of reaction rate and diastereoselectivity (Entry 2-4). More catalyst loading and 
higher temperature increased the reaction rate significantly (Entry1-2, 6-7). When 




50 wt% Pt/C at 70 oC was used for the hydrogenation, which afforded the 
products with 10% of compound 225 and a dr (223:224) of 8:1. 
The products of this step are not separable and they were used together in the 
following synthesis. With this result and our previous experience in hand, we 
carried out the rest synthesis without much problem (Scheme 3.2.9). 
 
Scheme 3.2.9 Total synthesis of (+)-alpha-yohimbine starting from 208ca 
 The inseparable mixture of 223 and 224 was treated with TFA in DCM at 0 oC, 
which afforded an inseparable diisomer mixture of free amine 226 (dr 8:1). The 
amine was confirmed via crude 1H NMR analysis and ESI mass analysis. Without 
purification, the mixture 226 was used in the reductive amination step directly. 
Unfortunately, the product 227 was inseparable again from the by-product 
2-(1H-indol-3-yl) ethanol that was generated from the reduction of 




2-(1H-indol-3-yl) acetaldehyde. The mixture of 227 and 2-(1-H-indol-3-yl) 
ethanol was isolated via flushing silica gel chromatography and used together in 
the transesterification step. When the mixture was treated with CSA in refluxing 
MeOH in a sealed tube, the acetyl group was cleaved and the tert-butyl ester was 
converted to methyl ester together, which afforded 228 in 31% yield over four 
steps. An increase in ee was observed during the analysis of compound 228 with 
chiral HPLC, the ee increased from 79% of IMDA product 209ca to 85% of 
compound 228. The compound 228 was fully characterized and the 
stereochemistry was established by NOESY analysis and also confirmed by 
comparing the 1H, 13C NMR with the reported data.6 The oxidative cyclization 
followed by NaBH4 reduction was subsequently carried out to finish the total 
synthesis of (+)-alpha-yohimbine. The final product was also fully characterized 
and confirmed by comparing the NMR data with the reported one.6 
 Since the ee of the starting IMDA product 208ca is 79% only, the total synthesis 
was carried out starting from IMDA products 208ha and 208hb (Scheme 3.2.10). 
which are inseparable. When the mixture of 208ha and 208hb was treated with 
Ni(COD)2 and DIBAL-H, two products 229 and 230 were obtained. By 
comparing the NMR data with that of compound 221, the trans isomer can be 
identified. The synthesis was completed in the same sequence as above. However, 
the ee for compound 228 was not increased and almost same as in scheme 3.2.9. 




low distereoselectivity (3.5:1) at the hydrogenation step. 
 
 
Scheme 3.2.10 Total synthesis of (+)-alpha-yohimbine starting from 208ha and 208hb 
 
3.3 Summary 
 In conclusion, we have found that a Brønsted-base catalyzed tandem 
isomerisation intramolecular-Diels-Alder reaction can be used to form useful 
hydroisoquinoline derivatives under mild conditions. The IMDA products have 
been obtained in moderate to high enantiomeric purity. This efficient method was 
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4.1 General information 
4.1.1 General procedures and methods  
 1H and 13C NMR spectras were recorded on a Bruker ACF300 (300MHz), Bruker 
DPX300 (300MHz) or AMX500 (500MHz) spectrometer. Chemical shifts are 
reported in parts per million (ppm). The residual solvent peak was used as an 
internal reference. Low-resolution mass spectras were obtained on a 
Finnigan/MAT LCQ spectrometer in ESI mode and a Finnigan/MAT 95XL-T 
mass spectrometer in FAB mode. All high-resolution mass spectras were obtained 
on a Finnigan/MAT 95XL-T spectrometer. Infrared spectras were recorded on a 
BIO-RAD FTS 165 FTIR spectrometer. Enantiomeric excess values were 
determined by chiral HPLC analysis on two sets: Jasco HPLC units, including a 
Jasco DG-980-50 Degasser, a LG-980-02 Ternary Gradient Unit, a PU-980 
Intelligient HPLC Pump, UV-975 Intelligient UV/VIS Detectors, and an AS-950 
Intelligient Sampler; Dionex Ultimate 3000 HPLC units, including a Ultimate 
3000 Pump, Ultimate 3000 variable Detectors. Optical rotations were recorded on 
Jasco DIP-1000 polarimeter. Melting points were determined on a BÜCHI B-540 
melting point apparatus. Analytical thin layer chromatography (TLC) was 
performed with Merck pre-coated TLC plates, silica gel 60F-254, layer thickness 
0.25 mm. Flash chromatography separations were performed on Merck 60 (0.040 
- 0.063mm) mesh silica gel. Toluene and THF were distilled from 




was distilled from CaH2 and was stored under N2 atmosphere. Other reagents and 
solvents were commercial grade and were used as supplied without further 
purification, unless otherwise stated.  
4.1.2 Materials  
 All commercial reagents were purchased from Sigma-Aldrich, Fluka, Alfa Aesar, 
Merck, TCI, and Acros of the highest purity grade. They were used without 
further purification unless specified. All solvents used, mainly hexane (Hex) and 
ethyl acetate (EtOAc), were distilled. Anhydrous DCM was freshly distilled from 
CaH2. Anhydrous THF was freshly distilled from Na/benzophenone. MeCN and 
CHCl3 were distilled from CaH2. MeOH was distilled from Mg.  
4.2 Preparation and characterization of compounds for the 
Michael reaction 
4.2.1 Preparation of alkynyl amines  
 
Alkynyl amines 141a-c were synthesized according to the equation above. To a 
flame-dried 50 ml rbf, pent-4-ynoic acid (2.9 mmol) and 5 ml THF were added 




aniline (3.4 mmol) in THF (5 ml) was added and the reaction mixture was stirred 
at rt for 18 hrs. The reaction mixture was filtered and the solvent was removed 
under reduced pressure. The residue was purified via flash chromatography. 
Amide 139a was obtained in 70% yield.  
 Then in a 50 ml dry rbf equipped with a condenser, amide 139a (2 mmol) was 
dissolved in 10 ml dry THF under N2, cooled to 0 
oC, LiAlH4 (5 mmol) was 
added. The mixture was refluxed at 70 oC overnight, and was then cooled to 0 oC, 
quenched with 1ml water, stirred untill a white solid was formed. Then the solid 
was filtered off and the filtrate was concentrated to afford the crude 140a.  
 Compound 140a was mixed together with 2 mmol of ethyl diazoacetate in 4 ml 
MeCN under N2. Then 0.2 mmol of copper iodide was added. The mixture was 
stirred overnight and the reaction was monitored with TLC until starting material 
was consumed. After concentrated under reduced pressure, the mixture was 
purified via chromatography on silco gel. Compound 141a was obtained in 60% 
yield over two steps. 
4.2.2 Representative procedure for Brønsted-base catalyzed tandem 
isomerization-aza-Michael reaction of alkynyl-amines 
 




was added and the mixture was stirred at rt for 24 hours. After concentrated, the 
mixture was purified by chromatography on silco gel. Compound 142a was 
obtained as pale yellow oil in 83% yield. 
(E)-ethyl 2-(1-phenylpiperidin-2-ylidene)acetate (142a): Yellow oil; 83% yield; 
1H NMR (300 MHz, CDCl3): δ 7.41 (t, J = 7.6 Hz, 2H), 7.26 (t, J = 7.6 Hz, 1H), 
7.16 (d, J = 7.3 Hz, 2H), 4.34 (s, 1H), 3.99 (q, J = 7.1 Hz, 2H), 3.47 (t, J = 6.0 Hz, 
2H), 3.24 (t, J = 6.4 Hz, 2H), 1.93-1.78 (m, 4H), 1.15 (t, J = 7.1 Hz, 3H) ppm; 13C 
NMR (75 MHz, CDCl3): δ 167.7, 162.2, 145.1, 128.9, 128.2, 125.8, 85.7, 57.2, 
51.0, 25.3, 22.7, 19.0, 13.6 ppm; IR (film): 3020, 2977, 2896, 1556, 1422, 1216, 
1137, 1046, 929 cm-1; LRMS (ESI) m/z: 268.1; HRMS (ESI) m/z: 
C15H19O2N
23Na1
+ ([M+Na]+), Calc. 268.1308, Found 268.1302. 
 
(E)-tert-butyl 2-(1-phenylpiperidin-2-ylidene)acetate (142b): Slight yellow 
solid; 70% yield; 1H NMR (300 MHz, CDCl3): δ 7.40 (t, J = 7.6 Hz, 2H), 
7.27-7.22 (m, 1H), 7.17 (d, J = 7.6 Hz, 2H), 4.32 (s, 1H), 3.44 (t, J = 6.0 Hz, 2H), 
3.20 (t, J = 6.4 Hz, 2H), 1.91-1.76 (m, 4H), 1.38 (s, 9H) ppm; 13C NMR (75 MHz, 
CDCl3): δ 168.8, 162.2, 146.4, 130.0, 126.8, 126.5, 89.1, 51.9, 28.6, 27.9, 26.3, 
23.8, 20.3 ppm; IR (film): 3020, 2978, 2897, 1524, 1378, 1216, 1129, 1046, 929 
cm-1; mp: 102.5 –103.9 °C; LRMS (ESI) m/z: 296.1; HRMS (ESI) m/z: 
C17H23O2N
23Na1





(E)-tert-butyl 2-(1-(2-tert-butylphenyl)piperidin-2-ylidene)acetate (142c):  
White solid; 70% yield; 1H NMR (300 MHz, CDCl3): δ 7.51-7.48 (m, 1H), 
7.28-7.25 (m, 2H), 7.05 (dd, J = 3.6, 5.6 Hz, 1H), 4.01 (s, 1H), 3.83-3.77 (m, 1H), 
3.40-3.30 (m, 2H), 2.57-2.49 (m, 1H), 1.95-1.59 (m, 4H), 1.36-1.35 (m, 18H) ppm; 
13C NMR (75 MHz, CDCl3): δ 168.6, 162.8, 146.5, 144.8, 130.1, 128.8, 127.8, 
127.6, 91.9, 53.8, 35.5, 31.2, 28.6, 26.1, 23.6, 20.6 ppm; IR (film): 3020, 2977, 
2896, 1524, 1424, 1218, 1129, 1046, 929 cm-1; mp: 113.5 –114.7 °C; LRMS (ESI) 
m/z: 352.1; HRMS (ESI) m/z: C21H31O2N
23Na1
+ ([M+Na]+), Calc. 352.2247, 
Found 352.2261. 
4.2.3 Synthesis of alkynyl amides and procedure for Brønsted-base catalyzed 
tandem isomerization-aza-Michael reaction 
 
 Compound 150 was obtained via the coupling of compound 139b with tButyl 
diazoacetate, 1 To a clear and dry vial, tert-butyl 7-(2-tert-butylphenylamino) 
-7-oxohept-3-ynoate (150) (36 mg, 0.1 mmol), a stirring bar and anhydrous THF 
(0.9 mL) were added in this sequence. After stirring at room temperature for a 
while, bicyclic guanidine 149 (2 mg, 0.01 mmol) in anhydrous THF (0.1 mL) 




days, the reaction mixture was concentrated and loaded onto a short silica gel 
column, followed by flash chromatography. Product 152 (24 mg) was obtained as 
white solid in 67% yield with 89% ee. 
 Synthesis of compounds 155,157, 159, 163, 166 follows the synthetic schemes in 
Scheme 2.2.6, chapter 5. Bicyclic guanidine catalyzed isomerization of these 
compounds follows the procedure above for compound 150 
N-(2-tert-butylphenyl)pent-4-ynamide (139b)  White solid; 62% yield; 1H 
NMR (300 MHz, CDCl3): δ= 7.52 (d, J = 7.41 Hz, 1H), 7.39 (d, J = 6.9 Hz, 1H), 
7.34 (s, 1H), 7.23-7.15 (m, 2H), 2.62 (d, J = 2.64 Hz, 4H), 2.03 (s, 1H), 1.41 (s, 
9H); 13C NMR (75 MHz, CDCl3):  δ= 169.4, 143.1, 134.8, 128.5, 126.8, 126.6, 
126.4, 82.9, 69.7, 36.4, 34.6, 30.8, 14.8; LRMS (ESI) m/z: 230.2. 
 tert-Butyl 7-(2-tert-butylphenylamino)-7-oxohept-3-ynoate (150) colorless oil; 
86% yield; 1H NMR (300 MHz, CDCl3): δ= 7.52 (d, J = 4.56 Hz, 1H), 7.47 (s, 
1H), 7.42 (d, J = 4.53 Hz, 1H), 7.25-7.19 (m, 2H), 3.17 (s, 2H), 2.69-2.64 (m, 4H), 
1.44 (s, 18H); 13C NMR (75 MHz, CDCl3): δ= 169.9, 167.8, 143.4, 135.1, 128.7, 
126.8, 126.6, 126.5, 82.1, 81.8, 74.0, 36.8, 34.7, 30.7, 27.9, 27.1, 15.3; LRMS 
(ESI) m/z: 366.1. 
(E)-tert-Butyl-2-(1-(2-tert-butylphenyl)-6-oxopiperidin-2-ylidene)acetate (152) 
white solid; 67% yield; 1H NMR (300 MHz, CDCl3): δ= 7.59 (d, J = 8.19 Hz, 1H), 
7.40 (t, J = 7.29 Hz, 1H), 7.31 (t, J = 1.47 Hz, 1H), 6.82 (d, J = 7.89 Hz, 1H), 4.49 




(m, 2H), 1.39 (s, 9H), 1.30 (s, 9H); 13C NMR (75 MHz, CDCl3): δ= 171.2, 166.9, 
156.9, 146.7, 135.5, 131.2, 129.8, 128.8, 127.6, 102.4, 79.6, 36.0, 34.0, 31.6, 28.3, 
25.7, 18.4; IR (film)/cm-1 : 2970, 1690, 1605, 1281, 1219, 1134, 771, 756; mp: 
145.1-146.0oC; LRMS (ESI) m/z: 366.1; HRMS (ESI): [M+Na]+ C21H29O3N
23Na1, 
Calc, 366.2040.  found, 366.2035; [α]29D  = -64.1 (c 0.1, CHCl3); HPLC analysis: 
Chiralpak IA+IA column ( Hexane/IPA=90/10, 1.0ml/min, 254nm, 25oC), 
11.33min(major), 12.31(minor), 89%ee. The geometry about the C=C bond was 
confirmed by NOSEY. 
tert-Butyl-6-(2-(2-tert-butylphenylamino)-2-oxoethoxy)hex-3-ynoate (153) 
colorless oil; 46% yield; 1H NMR (300 MHz, CDCl3): δ=8.61 (s, 1H) 7.83 (d, J = 
4.92 Hz, 1H), 7.39 (d, J = 4.92 Hz, 1H), 7.24 (t, J = 4.56 Hz, 1H), 7.14 (t, J = 4.56 
Hz, 1H), 4.16 (s, 1H), 3.75 (t, J = 4.26 Hz, 2H), 3.11 (t, J = 1.56 Hz, 2H), 2.59 (t, 
J = 5.28 Hz, 2H), 1.43 (s, 9H). 1.42 (s, 9H); 13C NMR (75 MHz, CDCl3): δ= 
167.7, 167.2, 141.4, 134.7, 126.8, 126.5, 125.9, 125.7, 81.8, 79.5, 73.9, 70.6, 69.9, 
34.4, 30.5, 27.9, 27.1, 20.3; LRMS (ESI) m/z: 396.1.    
tert-Butyl-5-(2-(2-tert-butylphenylamino)-2-oxoethoxy)-5-methylhex-3-ynoate 
(154) colorless oil; 40% yield; 1H NMR (300 MHz, CDCl3): δ= 8.64 (s, 1H), 7.98 
(d, J = 7.89 Hz, 1H), 7.38 (d, J = 7.89 Hz, 1H), 7.26-7.08 (m, 2H), 4.27 (s, 2H), 
3.19 (s, 2H), 1.56 (s, 6H), 1.46(s, 9H), 1.43 (s, 9H); 13C NMR (75 MHz, CDCl3): 
δ= 167.6, 166.8, 140.3, 134.9, 126.8, 126.3, 125.2, 124.9, 83.7, 82.0, 78.4, 71.8, 




tert-Butyl 6-(2-tert-butylphenylcarbamoyloxy)hex-3-ynoate 155  colorless oil; 
66% yield; 1H NMR (300 MHz, CDCl3): δ= 7.54 (s, 1H), 7.37 (d, J = 7.56 Hz,1H), 
7.24-7.01 (m, 2H), 4.25 (t, J = 7.02 Hz, 2H), 3.17 (s, 2H), 2.60 (t, J = 7.02 Hz, 
2H), 1.46 (s, 9H), 1.40 (s, 9H); 13C NMR (75 MHz, CDCl3): δ= 167.8, 154.1, 
135.1, 126.8, 126.4, 125.7, 81.7, 79.1, 73.9, 63.2, 34.6, 30.6, 27.9, 27.1, 19.7; 
LRMS (ESI) m/z: 382.1. 
tert-Butyl-5-(2-(2-tert-butylphenylamino)-2-oxoacetamido)pent-3-ynoate (156) 
colorless oil; 50% yield; 1H NMR (300 MHz, CDCl3): δ= 9.56 (s, 1H), 7.98 (d, J 
= 7.9 Hz, 1H), 7.88 (s, 1H), 7.42 (d, J = 7.9 Hz, 1H), 7.29-7.15 (m, 2H), 4.59 (s, J 
= 6.4 Hz,1H), 3.72 (s, 2H), 1.46-1.47 (m, 18H); 13C NMR (75 MHz, CDCl3): δ= 
166.4, 160.1, 156.5, 140.9, 133.9, 126.8, 126.5, 126.0, 124.0, 119.6, 116.5, 82.1, 
47.8,47.2, 34.2, 30.5, 27.8; LRMS (EI) m/z: 395.1.  
(S)-tert-Butyl 5-(N-(2-(2-tert-butylphenylamino)-2-oxoethyl)acetamido)penta 
-2,3-dienoate (157) colorless oil; 67% yield; 1H NMR (300 MHz, CDCl3): δ= 
8.19 (s, 1H), 7.52 (d, J = 7.29 Hz, 1H), 7.38 (d, J = 7.32 Hz, 1H), 7.23-7.12 (m, 
2H), 5.68-5.64 (m, 2H), 4.29-4.10 (m, 4H), 3.24 (s, 3H), 1.46-1.38(m, 18H); 13C 
NMR (75 MHz, CDCl3): δ= 211.3, 172.0, 167.4, 164.0, 142.8, 134.6, 127.8, 126.7, 
126.3, 93.1, 91.3, 81.7, 51.7, 47.8, 44.2, 34.5, 30.4, 28.0, 20.1. IR (film)/cm-1 
3016, 2399, 1682, 1520, 1474, 1427, 1211, 925. LRMS (ESI) m/z: 423.2; HRMS 
(ESI): [M+Na]+ C23H32O4N2
23Na1, Calc, 423.2254. found, 423.2259.  [α]29D  = 




column ( Hexane/IPA=80/20, 1.0ml/min, 230nm, 25oC), 29.45 min(major), 50.49 
min (minor), 65%ee. 
 (S)-tert-Butyl 5-(2-(2-tert-butylphenylamino)-2-oxoethoxy)-5-methylhexa-2,3 
-dienoate (158) colorless oil; 68% yield; 1H NMR (300 MHz, CDCl3): δ= 8.69 (s, 
1H), 8.02 (dd, J = 1.32, 7.89 Hz, 1H), 7.42 (dd, J =1.65, 8.07 Hz, 1H), 7.30-7.25 
(m, 1H), 7.18-7.12 (m, 1H), 5.70 (d, J =6.06, 1H), 5.59 (d, J =6.24, 1H), 4.17 (d, J 
=7.89, 2H), 1.52-1.48(m, 24H); 13C NMR (75 MHz, CDCl3): δ= 210.8, 167.34, 
164.3, 140.1, 134.9, 126.8, 125.2, 124.8, 100.1, 92.5, 81.6, 76.0, 63.4, 34.3, 30.4, 
28.1, 27.1, 26.6, 34.3, 30.4, 28.1, 26.6. IR (film)/cm-1 1959, 1697, 1527, 1288, 
1219, 1141, 1288, 1219, 1141, 1087, 910; LRMS (ESI) m/z: 410.2; HRMS (ESI): 
[M+Na]+ C23H33O4N1
23Na1, Calc, 410.2302.  found, 410.2321. [α]29D  = +45.1 (c 
1.2, CHCl3); HPLC analysis: Chiralpak IB column ( Hexane/IPA=90/10, 
1.0ml/min, 230nm, 25oC), 5.13min(major), 9.68(minor), 87%ee. 
(S)-tert-Butyl 5-(N-(2-(2-tert-butylphenylamino)-2-oxoethyl)acetamido)penta- 
2,3-dienoate (159) colorless oil; 67% yield; 1H NMR (300 MHz, CDCl3): δ= 8.19 
(s, 1H), 7.52 (d, J = 7.29 Hz, 1H), 7.38 (d, J = 7.32 Hz, 1H), 7.23-7.12 (m, 2H), 
5.68-5.64 (m, 2H), 4.29-4.10 (m, 4H), 3.24 (s, 3H), 1.46-1.38(m, 18H); 13C NMR 
(75 MHz, CDCl3): δ= 211.3, 172.0, 167.4, 164.0, 142.8, 134.6, 127.8, 126.7, 
126.3, 93.1, 91.3, 81.7, 51.7, 47.8, 44.2, 34.5, 30.4, 28.0, 20.1. IR (film)/cm-1 
3016, 2399, 1682, 1520, 1474, 1427, 1211, 925. LRMS (ESI) m/z: 423.2; HRMS 
(ESI): [M+Na]+ C23H32O4N2




+31.7 (c 0.5, CHCl3); HPLC analysis: PHENOMENEX Lux 5u Cellulose-2 
column ( Hexane/IPA=80/20, 1.0ml/min, 230nm, 25oC), 29.45 min(major), 50.49 
min (minor), 65%ee. 
4.3 Preparation and characterization of compounds for the IMDA 
reaction 
5.3.1 Synthesis and Characterizations of IMDA substrates     
 
 To a flame-dried 50 ml rbf, (2E,4E)-hexa-2,4-dienoic acid (2.9 mmol) and 5 ml 
THF was added under N2. This is followed by DCC (3.2 mmol) and HOBT (3.2 
mmol). Finally, propargyl amine (3.4 mmol) in THF (5 ml) was added and the 
reaction mixture was stirred at rt for 18 hrs. The reaction mixture was filtered and 
the solvent was removed under reduced pressure. The residue was purified via 
flash chromatography.  The resulting (2E,4E)-N-(prop-2-ynyl)hexa-2,4- 




diazoacetate catalyzed by CuI to afford comound 201 together with certain 
amount of inseparable allene in 60% yield. 
Representative procedure for the synthesis of IMDA substrates: 
Step 1: To a 200 ml rbf was added a stirring bar, 10 mmol LiOH.H2O and 10 ml 
DMF (AR grade), followed by the addition of 30 mmol Furfurylamine 6. The 
mixture was stirred vigorously. Then 10 mmol propargyl bromide 7 in 30 ml 
DMF was added slowly during 1 hour. After stirred for another 3 hours, the 
mixture was filtered through clite via sucktion and was washed thoroughly with 
Diethyl Ether. The filtrate was washed four times with water. The combined 
aqueous layer was extracted again with Diethyl Ether and the combined organic 
layers were washed with brine and dried over sodium sulphate, concentrated via 
rotary evaporation and purified by flushing silica gel chromatography 
(Hexane:EA=6:1). The product 8 was obtained as pale yellow oil in 80% yield. 
(Due to the low boiling point, 8 cannot be dried under vacumn and it was dried 




Step 2: To a solution of 8 (8 mmol) in dry DCM (50 mL) under nitrogen 
atmosphere was added Et3N (8.8 mmol, 1.1 eq). After the mixture was cooled to 0 
oC, pivaloyl chloride was added dropwisely. Then the reaction mixture was 
warmed to rt and stirred till full conversion indicated by TLC (usually around 1 
hour). The product was obtained as colorless oil in 95% yield by flushing silica 
gel chromatography purification. (Other substrates were prepared in the same way 
but with different acid chlorides or anhydrides) 
Step 3: (take 10a for example) Compound 9 (6 mmol) was dissolved in MeCN 
(AR grade) under N2, and 0.6 mmol CuI was added to the solution. The mixture 
was stirred for 10 minutes. Then ethyl diazoacetate(9 mmol) was added and the 
mixture was stirred under N2 for 10 hours. Check TLC to ensure full conversion 
of starting material 9 (if not, add a bit more diazo compound and stirred till 
completion). Rotary evaporate to remove solvent and load the mixture to silica gel 
column. After chromatography purification, the product 10a was obtained as 
colorless oil in 75% yield. The IMDA products (10aa and 10ab) were obtained 
together in around 10% yields. (Other IMDA substrates were prepared in the same 
way but with appropriate alkynes and dizao-compounds.) 
 
N-(furan-2-ylmethyl)prop-2-yn-1-amine (206): Pale yellow oil, 80% yield. 1H 
NMR (500 MHz, CDCl3) δ 7.36 (s, 1H), 6.31 (t, J = 1.4 Hz, 1H), 6.21 (d, J = 3.15 




CDCl3) δ 152.96, 142.06, 110.14, 107.48, 81.64, 71.67, 44.62, 37.16; LRMS 




N-(furan-2-ylmethyl)-N-(prop-2-ynyl)pivalamide (207a): colorless oil, 95% 
yield. 1H NMR (500 MHz, CDCl3) δ 7.35 (d, J = 1.25 Hz, 1H), 6.31 (q, 1H), 6.26 
(d, J = 3.15 Hz, 1H), 4.72(s, 2H), 4.14 (d, J = 2.5 Hz, 2H), 2.22 (t, J = 2.5 Hz, 
1H). 13C NMR (125 MHz, CDCl3) δ 177.10, 150.40, 142.39, 110.33, 108.75, 
79.02, 72.00, 43.25, 38.98, 36.37, 28.55; LRMS (ESI) m/z 220.1 (M + H+), 
HRMS (ESI) m/z 220.1339 ([M + H+]), calc. for [C13H17NO2+ H
+] 220.1259. 
 
tert-Butyl furan-2-ylmethyl(prop-2-ynyl)carbamate (207c): was prepared as 
below: To a solution of 206 (8 mmol) in dry DCM (50 mL) under nitrogen 
atmosphere was added Et3N (8.8 mmol, 1.1 eq). After the mixture was cooled to 0 
oC, Boc anhydride (8 mmol) was added dropwisely. Then the reaction mixture 
was warmed to rt and stirred till full conversion indicated by TLC (usually around 
1 hour). The product was obtained as colorless oil in 95% yield by flushing silica 
gel chromatography purification. Colorless oil, 1H NMR (500 MHz, CDCl3) δ 
7.34 (t, J = 2.0 Hz, 1H), 6.30 (q, 1H), 6.22 (br, 1H), 4.50(s, 2H), 4.05 (br, 2H), 




110.20, 108.00, 80.62, 79.18, 71.62, 42.18, 35.34, 28.27; LRMS (ESI) m/z 257.9 




Benzyl furan-2-ylmethyl(prop-2-ynyl)carbamate (207d): colorless oil, 90% 
yield. 1H NMR (500 MHz, CDCl3) δ 7.38-7.31 (m, 6H), 6.32-6.2 (m, 2H), 5.20 (s, 
2H), 4.60(s, 2H), 4.14-4.08 (m, 2H), 2.24 (s, 1H). 13C NMR (125 MHz, CDCl3) δ 
155.42, 150.42, 142.42, 136.36, 128.46, 128.05, 127.87, 110.30, 108.85, 108.47, 
78.71, 72.14, 67.70, 42.49, 42.20, 35.80. LRMS (ESI) m/z 292.0 (M + Na+), 
HRMS (ESI) m/z 292.0947 ([M + Na+]), calc. for [C16H15NO3+ Na
+] 292.1052. 
 
N-(furan-2-ylmethyl)-4-methyl-N-(prop-2-ynyl) benzenesulfonamide (207e): 
yellow solid, 85%yield. 1H NMR (500 MHz, CDCl3) δ 7.74-7.72 (d, J =8.8, 2H), 
7.33 (s, 1H), 7.28 (d, J =8.2, 2H), 6.30-6.28 (m, 2H), 4.43 (s, 2H), 4.01 (d, J =1.9, 
2H), 2.42 (s, 3H), 2.07(d, J = 2.5, 1H). 13C NMR (125 MHz, CDCl3) δ 148.57, 
143.58, 142.91, 135.93, 129.44, 127.68, 110.35, 109.94, 76.39, 73.90, 42.65, 
36.08, 21.47. LRMS (ESI) m/z 312.0 (M + Na+), HRMS (ESI) m/z 312.0673 ([M 
+ Na+]), calc. for [C15H15NSO3+ Na
+] 312.0773. 
 




oil, 90% yield. 1H NMR (500 MHz, CDCl3) δ 7.53 (d, J =8.2, 2H), 7.43 (d, J =8.2, 
2H), 7.37 (s, 1H), 6.31 (br, 2H), 4.76-4.54 (brm, 2H), 4.24-3.95 (brm, 2H), 2.31(s, 
1H). 13C NMR (125 MHz, CDCl3) δ 170.05, 149.26, 142.64, 133.95, 131.59, 
128.79, 124.36, 110.31, 109.27, 78.13, 72.65, 44.79, 40.61, 38.35, 34.43, 33.59, 
33.33. LRMS(ESI) m/z 339.9 (M + Na+), HRMS (ESI) m/z 339.9951，341.9932 




(207g) was prepared as below: 206 (1 mmol) was dissolved in 5 ml dry THF 
under N2, then DCC (1.1 mmol) and DMAP (0.1 mmol) were added. The mixture 
was stirred at rt for 30 mins. And then 2-(1H-indol-3-yl)acetic acid (1.1 mmol) 
was added and the mixture was left stirring overnight. The mixture was filtered 
through clite and then was concentrated and purified via silica gel 
chromatography. The product was obtained as a yellow solid in 70% yield.  
1H NMR (500 MHz, CDCl3) δ 8.34 (s, 1H), 7.62-7.60 (m, 1H), 7.40-7.32 (m, 2H), 
7.21-7.18 (m, 1H), 7.14-7.11 (m, 1H), 7.08-7.03 (m, 1H), 6.34-6.31 (m, 2H), 4.73 
(s, 1H), 4.61 (s, 1H), 4.28 (s, 1H), 4.04 (s, 1H), 4.01 (s, 1H), 3.95 (s, 1H), 2.24 (d, 
1H) . 13C NMR (125 MHz, CDCl3) δ 171.29, 150.44, 149.72, 142.74, 142.32, 
136.18, 127.13, 127.09, 122.7, 122.64, 122.16, 119.60, 118.59, 111.25, 110.30, 




31.33, 31.08. LRMS(ESI) m/z 293.0 (M + H+) , HRMS (ESI) m/z 315.1113 ([M + 
Na+]), calc. for [C18H16N2O2+ Na
+] 315.1212. 
 
Ethyl 5-( N - ( furan -2 - ylmethyl) pivalamido) pent -3 –ynoate (208a): 
colorless oil, 75% yield. 1H NMR (500 MHz, CDCl3) δ 7.34 (s, 1H), 6.31 – 6.30 
(m, 1H), 6.27 (d, J = 3.15, 1H), 4.72 (s, 2H), 4.21-4.16 (m, 4H), 3.27-3.26 (m, 
2H), 1.32 (s, 9H), 1.27 (t, J =6.9, 3H). 13C NMR (125 MHz, CDCl3) δ 177.09, 
168.15, 150.63, 142.30, 110.31, 108.69, 78.53, 75.97, 61.62, 43.07, 39.00, 36.80, 
28.58, 26.08, 14.12. LRMS (ESI) m/z 328.15 (M + Na+), HRMS (ESI) m/z 
328.1528 ([M + Na+]), calc. for [C17H23O4N + Na
+] 328.1628. 
 
tert-butyl 5-(N-(furan-2-ylmethyl)pivalamido)pent-3-ynoate (208b): colorless 
oil, 70% yield. 1H NMR (500 MHz, CDCl3) δ 7.32 (s, 1H), 6.29 (d, J =1.8, 1H), 
6.25 (d, J = 1.5, 1H), 4.70 (s, 2H), 4.16 (s, 2H), 3.16 (t, J =1.9, 2H), 1.44 (s, 9H), 
1.31 (s, 9H). 13C NMR (125 MHz, CDCl3) δ 177.00, 167.19, 150.69, 142.23, 
110.28, 108.61, 81.87, 78.20, 76.61, 42.98, 38.96, 36.83, 28.57, 27.94, 27.08. 
LRMS (ESI) m/z 356.15 (M + Na+), HRMS (ESI) m/z 356.1835 ([M + Na+]), 






tert-butyl 5-( tert - butoxycarbonyl (furan-2-ylmethyl) amino) pent- 3 – 
ynoate (208c): colorless oil, 80% yield. 1H NMR (500 MHz, CDCl3) δ 7.31 (s, 
1H), 6.27 (t, J =4.1, 1H), 6.21 (br, 1H), 4.49 (s, 2H), 4.05 (br, 2H), 3.16 (t, J =3.7, 
2H), 1.44 (d, 18H). 13C NMR (125 MHz, CDCl3) δ 167.25, 154.64, 151.25, 
142.01, 110.12, 107.83, 91.01, 81.72, 80.35, 78.35, 41.98, 35.59, 28.24, 27.97, 
27.84. LRMS (ESI) m/z 372.20 (M + Na+), HRMS (ESI) m/z 372.1787 ([M + 
Na+]), calc. for [C19H27O5N + Na
+] 372.1889. 
 
tert-Butyl -5-( (benzyloxycarbonyl) (furan -2-ylmethyl) amino ) pent -3- 
ynoate (208d):  colorless oil, 75% yield. 1H NMR (500 MHz, CDCl3) δ 
7.38-7.30 (m, 6H), 6.30-6.21 (m, 2H), 5.18 (s, 2H), 4.61 (s, 2H), 4.15-4.08 (m, 
2H), 3.19 (s, 2H), 1.46 (s, 9H).  13C NMR (125 MHz, CDCl3) δ 167.25, 154.64, 
151.25, 142.01, 110.12, 107.83, 91.01, 81.72, 80.35, 78.35, 41.98, 35.59, 28.24, 
27.97, 27.84. LRMS (ESI) m/z 406.20 (M + Na+), HRMS (ESI) m/z 406.1622 
([M + Na+]), calc. for [C22H25O5N + Na
+] 406.1733. 
 
tert-butyl 5-(N -(furan -2 -ylmethyl) -4 -methylphenylsulfonamido)pent - 3 - 
ynoate (208e) : yellow solid, 65% yield. 1H NMR (500 MHz, CDCl3) δ 7.74 (d, J 
=8.2, 2H), 7.34(s, 1H), 7.28 (d, J =8.2, 2H), 6.31 (dd, J =13.2 2H), 4.43 (s, 2H), 




CDCl3) δ 166.79, 148.83, 143.38, 142.90, 136.12, 129.38, 127.88, 110.38, 109.96, 
81.93, 78.52, 75.78, 42.78, 36.65, 27.94, 27.02, 21.52. LRMS (ESI) m/z 426.14 
(M + Na+), HRMS (ESI) m/z 426.1336 ([M + Na+]), calc. for [C21H25O5NS + 
Na+] 426.1453. 
 
tert-butyl 5-(4-bromo-N- ( furan- 2- ylmethyl) benzamido) pent- 3- ynoate 
(208f) : color- less oil , 65% yield. 1H NMR (500 MHz, CDCl3) δ 7.57 (d, J =8.2, 
2H), 7.48 (d, J =8.2, 2H), 7.40 (s, 1H), 6.35 (br, 2H), 4.83, 4.59 (br, 2H), 4.31, 
3.99 (br, 2H), 3.24 (t, J =2.2, 2H), 1.46 (s, 9H). 13C NMR (125 MHz, CDCl3) δ 
170.14, 167.01, 142.66, 134.26, 131.66, 128.95, 124.37, 110.37, 109.29, 81.98, 
77.57, 28.06, 27.95, 27.20. LRMS (ESI) m/z 454.10, 456.10 (M + Na+), HRMS 




tert-butyl 5- ( N - (furan -2 -ylmethyl) -2 -(1H-indol -3-yl)acetamido)pent-3- 
ynoate (208g): white solid, 60% yield. 1H NMR (500 MHz, CDCl3) δ 8.52 (s, 
1H), 7.63-7.59 (m, 1H), 7.39-7.7.30 (m, 2H),7.18-7.16(m, 1H), 7.11-7.09(m, 1H), 




(s, 1H), 3.99 (s, 1H), 3.94 (s, 1H), 3.18(t, J =1.9), 1.47(d, J =13.8, 9H). 13C NMR 
(125 MHz, CDCl3) δ 171.36, 171.32, 167.35, 167.13, 150.58, 149.94, 142.60, 
142.20, 136.18, 127.15, 127.10, 122.94, 122.85, 122.01, 121.94, 119.46, 119.40, 
118.60, 118.53, 118.49, 111.25, 111.19, 110.32, 110.29, 108.71, 108.57, 108.40, 
82.05, 81.86, 78.07, 77.67, 77.25, 77.00, 76.75, 76.39, 43.53, 41.35, 37.43, 34.44, 
31.36, 31.06, 27.90, 27.18, 27.09. LRMS (ESI) m/z 429.15 (M + Na+), HRMS 
(ESI) m/z 429.1792 ([M + Na+]), calc. for [C24H26O4N2 + Na
+] 429.1893. 
 
3-ethylpentan- 3 -yl 5-(tert-butoxycarbonyl(furan-2-ylmethyl)amino) pent- 
3-ynoate (208h): clorless oil, 70% yield. 1H NMR (500 MHz, CDCl3) δ 7.33 (s, 
1H), 6.30-6.28 (m, 1H), 6.21 (br, 1H), 4.50 (s, 2H), 4.09 (br, 2H), 3.20 (t, J 
=2.2,1H), 1.82 (q, J =15.2, 7.5, 6H), 1.49 (s, 9H), 0.82 (t, J =7.5, 9H). 13C NMR 
(125 MHz, CDCl3) δ 166.96, 154.68, 151.32, 142.04, 110.16, 108.31, 107.79, 
89.88, 80.41, 78.33, 42.10, 41.83, 41.71, 35.84, 35.64, 35.53, 28.29, 27.05, 26.66, 
7.59. LRMS (ESI) m/z 414.0 (M + Na+), HRMS (ESI) m/z 414.2265 ([M + Na+]), 
calc. for [C22H33O5N + Na
+] 414.2359. 
 
3-ethylpentan-3-yl 5-(N-(furan-2-ylmethyl)pivalamido)pent-3-ynoate (208i) : 




6.28-6.27 (m, 1H), 6.23 (d, J =3.1, 1H), 4.68 (s, 2H), 4.15 (s, 2H), 3.18 (t, J =1.2, 
2H), 1.8 (q, J =15.1, 7.5, 6H), 1.29 (s, 9H), 0.83 (t, J =7.5, 9H). 13C NMR (125 
MHz, CDCl3) δ 176.90, 166.71, 150.60, 142.14, 110.18, 108.47, 89.88, 77.99, 
42.87, 38.84, 36.72, 28.46, 27.23, 26.98, 26.62, 7.52. LRMS (ESI) m/z 398.1 (M 
+ Na+), HRMS (ESI) m/z 398.2296 ([M + Na+]), calc. for [C22H33O4N + Na
+] 
398.2410. 
4.3.2 Representative Procedure for Bicyclic guanidine catalyzed IMDA 
reactions and Characterizations of IMDA products  
 Substrate 208 (2 mmol) was dissolved in 100ml distilled hexane. Then bicyclic 
guanidine catalyst was added and the mixture was stirred at rt for appropriate days 
when TLC showed the starting material was almost completely consumed. The 
solvent was removed via rotary evaporation; further purification was completed 
by flushing silica gel chromatography. The products were obtained in 72-88% 
yields. The two diisomers can be separated by flushing silica gel chromatography 
for most of the substrates. For  208e, 208h, 208i, the IMDA product diisomers 
cannot be separated by silica gel chromatography, and the products were 
characterized by checking the crude 1H NMR. The IMDA products of 208h were 





208aa: colorless oil, 66%yield. 1H NMR (500 MHz, CDCl3) δ 6.39 (s, 2H), 5.74 
(t, J =1.8, 1H), 5.20 (d, J =4.4, 1H), 5.08 (d, J =12.6, 1H), 4.58 (d, J =17.6, 1H), 
4.12-4.06 (m, 2H), 3.73 (d, J =18.3, 1H), 3.69-3.67 (m, 1H), 3.03 (d, J =12.6, 1H), 
1.3(s, 9H), 1.22 (t, J =6.9, 9H). 13C NMR (125 MHz, CDCl3) δ 177.28, 169.78, 
135.73, 135.00, 134.90, 116.19, 84.27, 78.68, 60.83, 48.49, 45.47, 44.44, 38.95, 
28.28, 14.07. LRMS (ESI) m/z 305.9 (M + H+), HRMS (ESI) m/z 328.1528 ([M + 
Na+]), calc. for [C17H23NO4 + Na
+] 328.1627. [α]29D  = +129.1 (c 4.5, CHCl3); 
HPLC analysis: Chiralpak Ce2 (Hex/IPA = 70/30, 0.5 mL/min, 210 nm, 23°C), 
23.3, 47.3(major) min, 59.5% ee. 
 
208ab: colorless oil, 22%yield. 1H NMR (500 MHz, CDCl3) δ 6.42-6.39 (m, 2H), 
5.83-5.82 (m, 1H), 5.30 (d, J =1.9, 1H), 5.13 (d, J =12.6, 1H), 4.64-4.59 (m, 1H), 
4.26-4.18 (m, 2H), 3.73 (d, J =18.3, 1H), 3.07 (d, J =12,1H), 2.99 (s, 1H), 1.31(s, 
9H), 1.29 (t, J =7.6, 3H). 13C NMR (125 MHz, CDCl3) δ 177.27, 170.93, 136.67, 
135.31, 134.68, 116.79, 83.39, 80.22, 61.19, 47.71, 45.69, 44.69, 38.97, 28.31, 
14.21. LRMS (ESI) m/z 305.9 (M + H+), HRMS (ESI) m/z 328.1526 ([M + Na+]), 
calc. for [C17H23O4N + Na
+] 328.1627. [α]29D  = -156.7 (c 1.5, CHCl3); HPLC 
analysis: Chiralpak Ce2 (Hex/IPA = 70/30, 0.5 mL/min, 210 nm, 23°C), 37.4, 





208ba: colorless oil, 60%yield. 1H NMR (500 MHz, CDCl3) δ 6.39 (s, 2H), 5.70 
(s, 1H), 5.15 (d, J =4.4, 1H), 5.07 (d, J =12.6, 1H), 4.59 (d, J =17.6, 1H), 3.72 (d, 
J =18.3 1H), 3.61 (d, J =1.9, 1H), 3.04 (d, J =12.6,1H), 1.40 (s, 9H), 1.31(s, 9H).  
13C NMR (125 MHz, CDCl3) δ 177.34, 169.00, 153.88, 135.70, 134.99, 115.99, 
84.37, 81.30, 78.86, 49.55, 45.53, 44.64, 39.01, 28.35, 27.99. LRMS (ESI) m/z 
334.1 (M + H+), HRMS (ESI) m/z 356.1826 ([M + Na+]), calc. for [C19H27O4N + 
Na+] 356.1940. [α]29D  = +146.1 (c 1.0, CHCl3); HPLC analysis: Chiralpak 
IA+Ce1 (Hex/IPA = 80/20, 1.0 mL/min, 210 nm, 23°C), 10.8 (major), 12.0 min, 
83.5% ee. 
 
208bb: colorless oil, 15%yield. 1H NMR (500 MHz, CDCl3) δ 6.40-6.37 (m, 2H), 
5.80-5.78 (m, 1H), 5.24 (d, J =1.6, 1H), 5.12 (d, J =12.5, 1H), 4.61 (d, J =18, 1H), 
3.73 (d, J =17.8, 1H), 3.08 (d, J =12.6, 1H), 2.92-2.91 (m, 1H), 1.48 (s, 9H), 
1.31(s, 9H). 13C NMR (125 MHz, CDCl3) δ 177.19, 170.00, 136.47, 135.36, 
135.04, 116.21, 83.22, 81.34, 80.18, 48.37, 45.62, 44.66, 38.88, 29.59, 28.23, 
28.06. LRMS (ESI) m/z 334.1 (M + H+), HRMS (ESI) m/z 356.1819 ([M + Na+]), 
calc. for [C19H27O4N + Na
+] 356.1940. [α]29D  = -244.7 (c 0.3, CHCl3); HPLC 
analysis: Chiralpak IA+Ce1 (Hex/IPA = 80/20, 1.0 mL/min, 210 nm, 23°C), 12.8, 





208ca: colorless oil (white solid after standing at rt for a while), 70% yield. 1H 
NMR (500 MHz, CDCl3) δ 6.38 (br, 2H), 5.67 (br, 1H), 5.11 (d, J =4.4, 1H), 
4.77-4.63 (m, 1H), 4.48-4.31 (m, 1H), 3.57-3.52 (m, 2H), 3.02-2.93 (m, 1H), 
1.45(s, 9H), 1.38 (s, 9H). 13C NMR (125 MHz, CDCl3) δ 169.14, 154.39, 136.41, 
135.75, 135.07, 134.59, 116.69, 116.36, 84.02, 81.26, 80.26, 78.75, 49.40, 43.99, 
43.13, 42.66, 29.62, 28.36, 27.96. LRMS (ESI) m/z 372.1 (M + Na+), HRMS 
(ESI) m/z 372.1770 ([M + Na+]), calc. for [C19H27O5N + Na
+] 372.1188. [α]29D  = 
+99.2 (c 1.0, CHCl3); HPLC analysis: Chiralpak IA (Hex/IPA = 90/10, 0.5 
mL/min, 210 nm, 23°C), 6.3 (major), 6.9 min, 79.3% ee. 
 
208cb: colorless oil (white solid after standing at rt for a while), 21% yield. 1H 
NMR (500 MHz, CDCl3) δ 6.39 (br, 2H), 5.79 (br, 1H), 5.24 (s, 1H), 4.84-4.70 
(m, 1H), 4.53-4.38 (m, 1H), 3.62-3.52 (m, 1H), 3.13-3.04 (m, 1H), 2.92-2.90 (m, 
1H) 1.49(s, 9H), 1.48 (s, 9H). 13C NMR (125 MHz, CDCl3) δ 170.21, 154.55, 
136.71, 135.30, 134.28, 117.15, 116.59, 82.94, 81.34, 80.32, 80.21, 78.78, 49.43, 
48.31, 44.30, 43.24, 29.65, 28.39, 28.12, 27.99. LRMS (ESI) m/z 372.1 (M + 
Na+), HRMS (ESI) m/z 372.1770 ([M + Na+]), calc. for [C19H27O5N + Na
+] 
372.1889. [α]29D  = -167.5 (c 1.0, CHCl3); HPLC analysis: Chiralpak IA (Hex/IPA 





208da: colorless oil, 71% yield. 1H NMR (500 MHz, CDCl3) δ 7.37-7.31 (m, 5H), 
6.44-6.33 (m, 2H), 5.70 (d, J =23.3, 1H), 5.20-5.16 (m, 3H), 4.90-4.74 (m, 1H), 
4.56-4.44 (m, 1H), 3.70-3.61 (m, 2H), 3.16-3.05 (m, 1H), 1.41(s, 9H). 13C NMR 
(125 MHz, CDCl3) δ 169.09, 155.72, 155.19, 136.42, 135.27, 134.95, 134.87, 
134.70, 128.56, 128.17, 128.01, 116.31, 116.88, 83.92, 83.82, 81.37, 67.54, 49.52, 
43.83, 43.67, 43.52, 36.66, 31.44, 29.68, 28.01, 24.70. LRMS (ESI) m/z 406.1 (M 
+ Na+), HRMS (ESI) m/z 406.1162 ([M + Na+]), calc. for [C22H25O5N + Na
+] 
406.1733. [α] 29D  = +109.7 (c 1.2, CHCl3); HPLC analysis: Chiralpak IA 
(Hex/IPA = 90/10, 0.5 mL/min, 210 nm, 23°C), 11.4 (major), 13.0 min, 77% ee. 
 
208db:colorless oil, 18% yield. 1H NMR (500 MHz, CDCl3) δ 7.37-7.32 (m, 5H), 
6.42-6.29 (m, 2H), 5.80-5.75 (m, 1H), 5.24-5.16 (m, 3H), 4.92-4.78 (m, 1H), 
4.57-4.44 (m, 1H), 3.71-3.61 (m, 1H), 3.22-3.12 (m, 1H), 2.91(s, 1H), 1.48(s, 
9H). 13C NMR (125 MHz, CDCl3) δ 170.04, 155.12, 153.83, 136.82, 136.45, 
136.36, 135.43, 134.66, 134.35, 128.17, 128.50, 128.12, 127.94, 116.63, 116.07, 
82.68, 81.35, 80.25, 67.49, 48.45, 48.31, 44.03, 43.83, 43.71, 31.57, 29.62, 28.08, 
27.89. LRMS (ESI) m/z 406.1 (M + Na+), HRMS (ESI) m/z 406.1614 ([M + 
Na+]), calc. for [C22H25O5N + Na




HPLC analysis: Chiralpak IA (Hex/IPA = 90/10, 0.5 mL/min, 210 nm, 23°C), 
27.8 (major), 30.4 min, 77% ee. 
 
208fa: colorless oil, 60% yield. 1H NMR (500 MHz, CDCl3) δ 7.59 (d, J =8.2, 
2H), 7.35 (d, J = 8.2, 2H), 6.56-6.33 (m, 2H), 5.84-4.98 (m, 3H), 4.34-3.96 (m, 
2H), 3.67-3.66 (m, 1H), 3.41-3.14 (m, 1H), 1.44(s, 9H). 13C NMR (125 MHz, 
CDCl3) δ 170.17, 168.88, 136.18, 135.94, 135.68, 135.26, 135.04, 134.49, 131.83, 
128.79, 124.36, 115.65, 83.99, 81.51, 78.86, 67.49, 49.53, 47.71, 42.32, 27.99. 
LRMS (ESI) m/z 454.1, 456.1 (M + Na+), HRMS (ESI) m/z 454.0631, 456.0613 
([M + Na+]), calc. for [C21H22O4NBr + Na
+] 454.0732. [α]29D  = +46.65 (c 2.0, 
CHCl3); HPLC analysis: Chiralpak IA+IA (Hex/IPA = 80/20, 1.0 mL/min, 230 
nm, 23°C), 22.9 (major), 26.6 min, 65% ee. 
 
208fb: colorless oil, 23% yield. 1H NMR (500 MHz, CDCl3) δ 7.57 (d, J =7.5, 
2H), 7.32 (d, J = 8.4, 2H), 6.54-6.30 (m, 2H), 5.87-5.69 (m, 1H), 5.34-4.98 (m, 
2H), 4.36-3.71 (m, 2H), 3.44-3.18 (m, 1H), 2.93(d, J =1.9, 1H), 1.48(s, 9H). 13C 
NMR (125 MHz, CDCl3) δ 169.92, 137.01, 136.03, 135.78, 131.86, 128.72, 
124.81, 124.39, 115.92, 83.08, 81.58, 80.39, 48.47, 47.81, 42.60, 29.68, 28.12.  




([M + Na+]), calc. for [C21H22O4NBr + Na
+] 454.0732. [α]29D  = -68.7 (c 0.7, 
CHCl3); HPLC analysis: Chiralpak IA+IA (Hex/IPA = 80/20, 1.0 mL/min, 230 
nm, 23°C), 23.7, 28.9(major) min, 68% ee. 
 
208ga: pale yellow oil, 58% yield. 1H NMR (500 MHz, CDCl3) δ = 8.30 (dd, 
J=41.8, 13.1, 1H), 7.65 (dd, J=37.5, 7.9, 1H), 7.35 (d, J=8.0, 1H), 7.20 (t, J=7.5, 
1H), 7.13 (t, J=7.4, 1H), 7.04 (s, 1H), 6.41 (dd, J=18.5, 5.6, 1H), 6.04 (dd, 
J=265.8, 5.6, 1H), 5.68 (d, J=47.2, 1H), 5.14 (dd, J=22.6, 4.2, 1H), 4.98 (dd, 
J=396.4,12.6, 1H), 3.98 (s, 1H), 3.91 (d, J=5.0, 1H), 3.67 (dd, J=138.35, 17.8, 
1H), 3.61 (dd, J=16.5, 1.9, 1H), 3.09 (dd, J=12.7, 1H), 1.41 (d, J=9.6, 9H). 13C 
NMR (125 MHz, CDCl3) δ = 171.15, 171.12, 169.09, 169.00, 136.30, 136.20, 
135.88, 135.30, 134.92, 134.07, 127.11, 127.01, 122.75, 122.53, 122.36, 122.27, 
119.84, 119.68, 118.99, 118.65, 116.21, 115.52, 111.31, 108.71, 84.24, 83.93, 
81.52, 81.48, 78.95, 78.82, 77.32, 77.07, 76.81, 49.50, 45.88, 45.67, 42.38, 41.54, 
32.13, 31.89, 28.03, 28.00.  LRMS (ESI) m/z 407.10 (M + H+), HRMS (ESI) 
m/z 429.1780 ([M + Na+]), calc. for [C24H26O4N2 + Na
+] 429.1893. [α]29D  = 
+141.2 (c 2.5, CHCl3); HPLC analysis: Chiralpak AD+AD (Hex/IPA = 80/20, 1.0 





208gb: pale yellow oil, 14.5% yield. 1H NMR (500 MHz, CDCl3) δ 8.18 (d, 
J=28.6, 1H), 7.66 (dd, J =35.6, 7.8, 1H), 7.37 (d, J =8.2, 1H), 7.22-7.21 (m, 1H), 
7.19-7.06 (m, 2H), 6.38 (s, 1H), 6.06 (dd, J = 293, 5.5, 1H), 5.73 (d, J = 56.6, 
1H), 5.01(dd, J =388, 12.7, 1H), 5.21 (d, J =23.4, 1H), 4.19 (dd, J = 678.4,19.0, 
1H), 4.07 (dd, J = 494.2, 17.1, 1H), 3.15 (dd, J = 420, 12.9, 1H), 2.88-2.84 (m, 
1H), 1.46 (d, J =3.7, 9H). 13C NMR (125 MHz, CDCl3) δ 170.96, 170.87, 170.03, 
169.99, 136.89, 135.68, 135.54, 133.70, 127.03, 122.58, 122.47, 122.39, 122.13, 
119.93, 119.76, 119.09, 118.61, 116.55, 115.68, 111.20, 109.01, 83.13, 82.80, 
81.51, 81.44, 80.35, 80.26, 77.25, 77.00, 76.75, 49.48, 48.52, 48.26, 46.06, 45.68, 
42.36, 41.70, 32.15, 32.01, 28.11, 28.00. LRMS (ESI) m/z 407.0 (M + Na+), 
HRMS (ESI) m/z 429.1775 ([M + Na+]), calc. for [C24H26O4N2 + Na
+] 429.1893. 
[α]29D  = -116.2 (c 4.5, CHCl3); HPLC analysis: Chiralpak AD+AD (Hex/IPA = 
80/20, 1.0 mL/min, 254 nm, 23°C), 34.7, 46.5 min(major), 70% ee. 
4.4 Procedures towards (+)-alpha-yohimbine and characterization of 
compounds 
 
 Compound 208ga (0.5 mmol) was dissolved in MeOH (3 ml), 10 % Pd/C (50 
mg) was added and reaction vassel was evacuated and recharged with H2 using a 




remove Pd/C, and the product 210 was obtained as pale yellow oil after 
chromatography on silco gel.  
210: pale yellow oil, 75% yield. 1H NMR (500 MHz, CDCl3) δ 56(brd, J =13.25, 
1H), 7.62 (t, J =8.85, 1H), 7.33 (d, J =8.15, 1H), 7.18 (t, J =7.6, 1H), 7.12(t, J 
=7.6, 2H), 7.02 (d, J =11.35, 1H), 4.92 (d, J =14.5, 0.5H), 4.72-4.66 (m, 1H), 
4.59(d, J =12.6, 0.5H), 4.20(d, J =15.15, 0.5H), 4.01-3.81(m, 2H), 3.34(d, J 
=15.15, 0.5H ), 3.03(d, J =14.5, 0.5H), 2.94 (t, J =12.6, 0.5H), 2.67 (s, 0.5H), 
2.57-2.54(m, 1H), 2.27-2.22 (m, 1H), 1.94(s, 0.5H), 1.80-1.57 (m, 4.5H), 1.48 (d, 
J =6.3, 9H). 13C NMR (125 MHz, CDCl3) δ 171.17, 170.72, 136.28, 136.23, 
127.33, 127.08, 122.83, 122.72, 121.95, 119.39, 118.76, 118.53, 111.30, 111.26, 
109.15, 108.99, 83.82, 83.76, 81.06, 78.72, 78.43, 57.26, 57.17, 49.21, 44.60, 
44.57, 42.76, 42.21, 41.24, 33.18, 33.00, 31.39, 31.14, 31.06, 30.62, 28.11, 27.07, 
26.97. LRMS (ESI) m/z 433.1 (M + Na+), HRMS (ESI) m/z 433.2100, ([M + 






 Compound 208ca (1 mmol) was dissolved in MeOH (4 ml), 10 % Pd/C (100 mg) 
was added and reaction vassel was evacuated and recharged with H2 using a 
balloon. Stirred untill 208ca was completely consumed. Filter through clite to 
remove Pd/C, and the products 211 and 212 were obtained as colorless oil in 20% 
and 70% yields respectively after chromatography on silco gel. The two products 
become solid after standing at rt for a while. 
211: Colorless oil, 20% yield. 1H NMR (500 MHz, CDCl3) δ 4.76 (d, J =5.0, 1H), 
4.29-3.96 (m, 2H), 3.07 (brs, 1H), 2.7 (d, J =8.8, 1H), 2.55 (brs, 1H), 2.17-2.12 
(m, 1H), 1.76-1.73 (m, 1H), 1.55(brs, 1H), 1.47-1.22(m, 22H). 13C NMR (125 
MHz, CDCl3) δ 170.78, 154.98, 81.62, 80.96, 79.67, 78.49, 53.27, 45.03, 33.06, 
30.68, 28.44, 28.20, 25.28. LRMS (ESI) m/z 376.0 (M + Na+), HRMS (ESI) m/z 
376.2107 ([M + Na+]), calc. for [C19H31O5N + Na
+] 376.2202. 




4.26 (brs, 1H), 4.03 (brs, 1H), 3.10-3.03 (m, 1H), 2.61 (brs, 2H), 2.19-2.15 (m, 
1H), 1.76-1.71 (m, 3H), 1.64-1.56(m, 2H), 1.55-1.24(m, 19H). 13C NMR (125 
MHz, CDCl3) δ 171.10, 154.80, 83.31, 80.64, 79.33, 78.28, 56.90, 42.26, 32.95, 
30.54, 28.24, 27.90, 26.73. LRMS (ESI) m/z 376.0 (M + Na+), HRMS (ESI) m/z 
376.2107 ([M + Na+]), calc. for [C19H31O5N + Na
+] 376.2202. 
The compound 212 (0.5 mmol) was dissolved in 3 ml DCM and cooled to 0 oC, 
then 0.75 ml TFA was added and the reaction mixture was stirred at 0  oC for 10 
mins . The reaction was monitored with TLC. After the reaction was finished, the 
reaction mixture was quenched with saturated NaHCO3 and was extracted with 
DCM for four times. The combined organic layers were dried over Na2SO4, and 
then was concentrated and dried under vacumn. The crude product was used 
directly in the next step. 
213 (crude product from above), HOBz(5.0 mmol) and NaCNBH3 (3.5 mmol) 
were mixed in 5 ml toluene in a 50 ml rbf under N2, the mixture was stirred for 30 
minutes at rt. Then 2-(1H-indol-3-yl)acetaldehyde (freshly prepared from methyl 
2-(1H-indol-3-yl)acetate (2.5 mmol) via DIBAL-H reduction) in another 5 ml 
toluene was added and the reaction mixture was stirred at rt overnight. Then the 
reaction mixture was quenched with saturated NaHCO3 and was extracted with 
DCM for four times. The combined organic layers were dried over Na2SO4, and 
were concentrated and purified via silica gel chromatography to afford 214 as 




214: colorless oil, 60% yield. 1H NMR (500 MHz, CDCl3) δ 8.17 (s, 1H), 7.60 (d, 
J =7.6, 1H), 7.33 (d, J =8.2, 1H), 7.17 (t, J =7.0, 1H), 7.10 (t, J =7.0, 1H), 7.00 (s, 
1H), 4.71 (t, J =5.0, 1H), 3.35 (d, J =13.2, 1H), 3.03-2.96 (m, 3H), 2.77-2.66 (m, 
3H), 2.37 (d, J =13.2, 1H), 2.13-2.10 (m, 1H), 2.00 (t, J =11.4, 1H), 1.86-1.82(m, 
1H), 1.78-1.72(m, 1H), 1.65-1.59(m, 1H), 1.57-1.49(m, 3H), 1.47(s, 9H). 13C 
NMR (125 MHz, CDCl3) δ 171.65, 136.21, 127.47, 121.77, 121.51, 119.06, 
118.80, 114.36, 111.05, 84.39, 80.71, 78.60, 59.37, 57.52, 56.76, 52.56, 42.00, 
33.72, 31.69, 28.07, 26.80, 22.83. LRMS (ESI) m/z 397.2 (M + H+), HRMS (ESI) 
m/z 419.2287 ([M + Na+]), calc. for [C24H32O3N2+ Na
+] 419.2413. 
The compound 214 (0.25 mmol) was dissolved in 4 ml MeOH in a sealed tube, 
then CSA (0.5 mmol) was added and the mixture was heated to 80 oC. After 24 
hours, the mixture was cooled to rt and MeOH was evaporated away. Then the 
mixture was dissolved in DCM and was quenched with 1 M NaOH. Extraction 
was done with DCM for four times. The combined organic layers were dried over 
Na2SO4, then was concentrated and purified via flushing silica gel 
chromatography. Compound 215 was obtained as a white solid in 80% yield. 
215: white solid, 80% yield. 1H NMR (500 MHz, CDCl3) δ 8.14 (s, 1H), 7.60 (d, J 
=8.2, 1H), 7.34 (d, J =7.55, 1H), 7.19 (dt, J =7.0, 1H), 7.10 (t, J =8.2, 1H), 7.00 
(d, J =2.5, 1H), 4.76 (t, J =5.0, 1H), 3.71 (s, 3H), 3.37 (dd, J =10.0, 1.3, 1H), 
3.03-2.96 (m, 3H), 2.79-2.66 (m, 3H), 2.38 (d, J =13.25, 1H), 2.20-2.15 (m, 1H), 




NMR (125 MHz, CDCl3) δ 172.89, 136.20, 127.47, 121.79, 121.50, 119.07, 
118.78, 114.36, 111.04, 84.37, 78.44, 59.32, 56.69, 56.50, 52.56, 52.50, 51.76, 
42.34, 33.70, 31.76, 27.07, 22.85. LRMS (ESI) m/z 355.1 (M + H+), HRMS (ESI) 
m/z 355.2024 ([M + H+]), calc. for [C21H26O3N2 + H
+] 355.1943. 
 Compound 215 (0.08 mmol) was dissolved in 1.5 ml EtOH, then an aqueous 
solution of Hg(OAc)2 and EDTA-2Na (1:1, 2.4 ml of a 0.1 M solution in water, 
0.24 mmol) was added. The resulting solution was heated to 85  oC and refluxed 
for 3 hours. Then the mixture was cooled down to 0  oC and 2.5 ml 25% HClO4 
was added and stirred at 0 oC for 10 minutes. The mixture was then extracted with 
DCM (4x5 ml), the combined organic layers was washed with brine, dried over 
Na2SO4 and concentrated via rotary evaporation. The residue was redissolved in 
MeOH:H2O (9:1, volume ratio, 2.5 ml). The PH was adjusted to 6 using 5% 
NaHCO3 solution. The mixture was cooled to 0 
oC, and NaBH4 (0.6mmol, 25mg) 
was added. Then the reaction was brought to rt and stirred for 1 hour. The solvents 
were removed under reduced pressure, and the residue was partitioned between 
cold 10%NH4OH and DCM, the aqueous layer was extracted with DCM for 4 
times, and the combined organic layers were dried (Na2SO4) and evaporated under 
reduced pressure. The residue was purified by flushing silco gel chromatography 
(Hexane:EA 1:1, then DCM: MeOH 20:1) to afford 217 as white foam in 30% 
yield. 




J =7.55, 1H), 7.30 (d, J =8.2, 1H), 7.14-7.07 (m, 2H), 4.83 (t, J =5.0, 1H), 3.67 (s, 
3H), 3.28 (d, J =10.7, 1H), 3.24-3.20 (m, 2H), 3.11-3.07 (m, 1H), 2.99-2.94 (m, 
1H), 2.79(dd, J =26.17, 10.1, 1H), 2.74-2.69 (m, 2H), 2.34-2.19(m, 3H), 
2.01-1.96(m, 1H), 1.75-1.70(m, 1H), 1.63-1.52(m, 2H). 13C NMR (125 MHz, 
CDCl3) δ 172.89, 136.20, 127.47, 121.79, 121.50, 119.07, 118.78, 114.36, 111.04, 
84.37, 78.44, 59.32, 56.69, 56.50, 52.56, 52.50, 51.76, 42.34, 33.70, 31.76, 27.07, 
22.85. LRMS (ESI) m/z 353.25 (M + H+), HRMS (ESI) m/z 353.1851 ([M + H+]), 
calc. for [C21H24O3N2 + H
+] 353.1787. 
 
 Compound 217 (0.1 mmol) was dissolved in dry DCM under N2 in a dry rbf, 
then 0.5 eq of triflic acid was added. The mixture was stirred at rt for12 hrs untill 
compound 217 was completely consumed. Purification by flushing silica gel 
chromatography afforded 218 as colorless oil in 50% yield. 
218: colorless oil, 50% yield. 1H NMR (500 MHz, CDCl3) δ 7.78 (s, 1H), 7.48 (d, 
J =7.55, 1H), 7.31 (d, J =8.2, 1H), 7.15 (t, J = 6.95, 1H), 7.10 (t, J = 6.95, 1H), 
5.87 (d, J =9.45, 1H), 5.73-5.70 (m, 1H), 3.86 (s, 3H), 3.82-3.81 (m, 1H), 3.32 (d, 
J = 12, 1H), 3.10-3.04 (m, 2H), 2.97-2.95 (m, 1H), 2.89 (d, J = 10.1, 1H), 
2.74-2.69(m, 2H), 2.41 (d, J = 10.7, 1H), 2.40-2.21(m, 1H), 1.96 (d, J = 19.55, 
1H), 1.84-1.79(m, 1H), 1.47-1.44 (m, 1H). 13C NMR (125 MHz, CDCl3) δ 174.30, 




69.64, 66.70, 59.13, 52.81, 52.04, 422.61, 41.43, 33.66, 29.10, 21.88. LRMS 




 In glovebox, to a100ml rbf was add 208ca (2 mmol), then 8 mmol of PPh3 and 2 
mmol of Ni(COD)2 was added. The mixture was dissolved in 20 ml dry toluene. 
After stirring in glovebox for 1 hour at rt, the rbf was sealed with a rubber septum 
and taken out of the glovebox. Under protection of N2 balloon, the mixture was 
cooded to 0oC. 2.5 mmol DIBAL-H (1 M in toluene) was diluted with 20 ml dry 
toluene and was added to the mixture slowly during 1 hour using a syringe pump. 
After addition, the reaction was monitored with TLC, if there is still a lot of 
starting material (due to the inaccurate concentration) remained. A bit more 
DIBAL-H should be added to ensure full conversion. After full conversion, the 
reaction mixture was quenched with saturated NH4Cl solution, and was extracted 
with DCM (4x50 ml), the combined organic layers were dried over Na2SO4, 
concentrated and purified by flushing silica gel chromatography. 221 was 





(5S,6S)-di-tert-butyl 6-hydroxy -3,5,6,7- tetrahydroisoquinoline 
-2,5(1H)-dicar- boxylate (221): colorless oil, 50% yield. 1H NMR (500 MHz, 
CDCl3) δ 5.54(brs, 1H), 5.48 (brs, 1H), 4.19-4.15 (m, 1H), 4.07-3.98 (t, J =16.3, 
2H), 3.94(t, J =23.35, 2H), 3.19 (dd, J =8.2, 1.9, 1H), 2.56-2.50(m, 1H), 2.21(dd, 
J = 17.65, 6.95, 1H), 2.06 (brs, 1H), 1.49(s, 9H), 1.45(s, 9H). 13C NMR (125 
MHz, CDCl3) δ 171.26, 154.60, 129.45, 121.69, 119.90, 81.66, 79.92, 67.80, 
54.38, 45.42, 43.70, 32.42, 28.40, 28.15. LRMS (ESI) m/z 374.2 (M + Na+), 
HRMS (ESI) m/z 374.1940, ([M + Na+]), calc. for [C19H29O5N + Na
+] 374.2046. 
[α]29D  = +46.2 (c 0.3, CHCl3); HPLC analysis: Chiralpak IC(Hex/IPA = 90/10, 
1.0 mL/min, 230 nm, 23°C), 13.1 (major), 17.5 min, 75.6% ee. 
 
In a dry rbf, 221 (0.6 mmol) was dissolved in 12ml dry DCM under N2, cooled 
to 0oC, then Et3N (0.9 mmol) and DMAP (0.06 mmol) were added. Finally, Ac2O 
(0.9 mmol) was added and the reaction mixture was brought to rt and stirred. The 
reaction was monitored with TLC untill completion (usually around 10 hours). 
Rotary evaporate to remove solvent and purified by flushing silica gel 
chromatography. 222 was obtained as colorless oil in 80% yield.  
(5S,6S)-di-tert-butyl 6- acetoxy -3,5,6,7-tetrahydroisoquinoline-2,5(1H)- 
dicarboxyl- ate (222): colorless oil, 80% yield. 1H NMR (500 MHz, CDCl3) δ 




1.85, 1H), 2.65(dt, J =17.65, 4.4, 1H), 2.18 (dd, J =17.0, 5.1, 1H), 2.00(s, 3H), 
1.44 (d, J =3.8, 18H). 13C NMR (125 MHz, CDCl3) δ 170.01, 169.89, 154.65, 
129.32, 128.81, 119.13, 81.44, 79.22, 69.95, 51.17, 43.71, 29.47, 28.39, 27.95, 
21.04. LRMS (ESI) m/z 416.1 (M + Na+), HRMS (ESI) m/z 416.2055, ([M + 
Na+]), calc. for [C21H31O6N + Na
+] 416.2151. [α]29D  = +20.2 (c 5.0, CHCl3); 
HPLC an alysis: Chiralpak IC(Hex/IPA = 90/10, 1.0mL/min, 254 nm, 23°C), 
14.4, 21.01(major) min, 79% ee. 
 
 222(0.25 mmol, 110 mg) was dissolved in 2.5 ml EtOH in a 10 ml schlenk flask 
which was equipped with an adapter attaching with a H2 balloon, and then Pt/C 
(50 wt%, 55 mg) was added. The system was evacuated and charged with H2 (4 
times). The reaction mixture was heated to 70 oC, and left stirred for 4 days. The 
reaction was monitored by checking curde 1H NMR untill the reaction was 
finished. Pt/C was filtered off and the filtrate was concentrated and used directly 
in the next step without further purification. Crude 1H NMR shows that a mixture 
223 of diisomers (8:1) was obtained. 
 




TFA was added and the reaction mixture was stirred at 0 oC for 10 mins . The 
reaction was monitored with TLC. After the reaction was finished, the reaction 
was quenched with saturated NaHCO3 and extracted with DCM for 4 times. The 
combined organic layers were dried over Na2SO4, then was concentrated and 
dried under vacumn. The crude product (a mixture of diisomers 8:1 shown by 
crude 1H NMR) was used directly in the next step.  
 
 226 (crude product form above), HOBz and NaCNBH3 were mixed in 5ml 
toluene in a 50ml rbf under N2, the mixture was stirred for 30 minutes at rt. Then 
2-(1H-indol-3-yl)acetaldehyde (freshly prepared from methyl 2-(1H-indol-3-yl) 
acetate via DIBAL-H reduction) in another 5ml toluene was added and the 
reaction mixture was stirred at rt overnight. Then the reaction mixture was 
quenched with saturated NaHCO3 and extracted with DCM for 4 times. The 
combined organic layers were dried over Na2SO4, then was concentrated and 
purified via silica gel chromatography. A mixture of 227 and 
2-(1H-indol-3-yl)ethanol which is produced from the reduction of the aldehyde 
was obtained as evidenced by crude 1H NMR. The mixture can not be separated 





 The mixture of 227 and 2-(1H-indol-3-yl)ethanol, obtained from above, was 
dissolved in 4 ml MeOH in a sealed tube, then CSA (0.25 mmol) was added and 
the mixture was heated to 80 oC. After 24 hours, the mixture was cooled to rt and 
MeOH was evaporated away. Then the mixture was dissolved in DCM and was 
quenched with 1 M NaOH. Extraction was done with DCM for four times. The 
combined organic layers were dried over Na2SO4, then was concentrated and 
purified via flushing silica gel chromatography. Compound 228 was obtained as 
white foam in 31% yield over four steps. 
(4S,5S,6S,8S)-methyl-(2-(1H-indol-3-yl)ethyl)-6-hydroxydecahydroisoquinoli
ne-5-carboxylate 228: white foam, 31% yield over 4 steps. 1H NMR (500 MHz, 
CDCl3) δ 7.95(br, 1H), 7.60 (d, J=8.2, 1H), 7.35 (d, J=8.2, 1H), 7.18 (t, J= 7.6, 
1H), 7.11(t, J= 6.9, 1H), 7.04(brs, 1H), 4.05(dt, J= 11.1, 3.8, 1H), 3.74 (s, 3H), 3.0 
(brd, J=10.7, 1H), 2.93-2.89(m, 4H), 2.68-2.62(m, 1H), 2.59-2.53(m, 1H), 2.48 
(dd, J=10.1, 5.5, 1H), 2.20-2.16(m, 2H), 2.10-2.05(m, 2H), 1.93(brt, J= 11.7, 2.0, 
1H), 1.77-1.69(m, 2H), 1.54-1.51 (m, 1H), 1.36 (dq, J= 24.9, 11.0, 3.8, 1H), 
1.21-1.18 (m, 1H). 13C NMR (125 MHz, CDCl3) δ 174.85, 136.18, 127.57, 
121.91, 121.48, 119.16, 118.82, 114.77, 111.04, 66.11, 59.35, 58.85, 54.69, 54.62, 




HRMS (ESI) m/z 357.2176, ([M + H+]), calc. for [C21H28O3N2 + H
+] 357.2100. 
[α] 29D  = +6.7 (c 0.8, CHCl3); HPLC analysis: Chiralpak IC (Hex/IPA = 
90/10(30mins)70/30, 1.0 mL/min, 254 nm, 23°C), 37.8, 40.2 (major) min, 
85.3% ee. 
 Reported data2 : 1H NMR (CDCl3, 360 MHz) δ 8.11 (brs, 1H), 7.59 (d, J =7.5, 
1H), 7.33 (d, J =7.5, 1H), 7.17 (t, J =7.5, 1H), 7.10 (t, J =7.5, 1H), 7.01 (brs, 1H), 
4.04 (ddd, J =11.0 , 10.5 , 4.0 , 1H) , 3.73 (s , 3H) , 2.97 (brd , J =12.0, 1H), 
2.80-2.95 (m, 4H), 2.52-2.70 (m, 2H), 2.48 (dd, J =10.5, 5.0, 1H), 1.98-2.22 (m, 
4H), 1.92 (brt, J =12.0Hz, 1H), 1.65-1.80 (m, 2H), 1.51 (m, 1 H), 1.35 (dq, J =3.0, 
12.0Hz, 1H), 1.20 (m, 1H); 13C NMR (CDCl3,) δ 174.6, 136.2, 127.5, 121.7, 
121.6, 119.0, 118.7, 111.4, 111.0, 66.0, 59.3, 58.7, 54.6, 54.5, 51.6, 37.8, 36.6, 
33.2, 24.5, 23.3, 22.7; mass spectrum, m/e 356.2092 (C21H28N2O3, requires 
m/e356.2100). 
 
 228 (28 mg, 0.08 mmol) was dissolved in 1.5 ml EtOH, then an aqueous solution 
of Hg(OAc)2 and EDTA-2Na (1:1, 2.4 ml of a 0.1 M solution in water, 0.24 mmol) 
was added. The resulting solution was heated to 85 oC and refluxed for 3 hours. 
Then the mixture was cooled down to 0 oC and 2.5 ml 25% HClO4 was added and 




the combined organic layers were washed with brine, dried over Na2SO4 and 
concentrated via rotary evaporation. The residue was redissolved in MeOH:H2O 
(9:1, volume ratio, 2.5 ml). The PH was adjusted to 6 using 5% NaHCO3 solution. 
The mixture was cooled to 0 oC, and NaBH4 (0.6 mmol, 25 mg) was added. Then 
the reaction was brought to rt and was stirred for 1 hour. The solvent was removed 
under reduced pressure, and the residue was partitioned between cold 
10%NH4OH and DCM, the aqueous layer were extracted with DCM for four 
times, and the combined organic layers were dried (Na2SO4) and evaporated under 
reduced pressure. The residue was purified by flushing silica gel chromatography 
(Hexane: EA 1:1, then DCM: MeOH 20:1) to afford 1 as white foam in 30% 
yield. 
 (+)-Alpha-Yohimbine 170: white foam, 30% yield. 1H NMR (500 MHz, 
CDCl3) δ 7.74(brs, 1H), 7.46 (d, J =7.8, 1H), 7.30 (d, J =8.0, 1H), 7.13 (t, J = 7.7, 
1H), 7.08(t, J = 7.6, 1H), 4.00(dt, J = 10.9, 4.3, 1H), 3.84 (s, 3H), 3.15 (brd, J 
=11.2, 1H), 2.99-2.92(m, 2H), 2.84(dd, J =11.3, 1.8, 1H), 2.70-2.67(m, 2H), 
2.61-2.50(m, 3H), 2.45-2.41(m, 1H),  2.10-2.04(m, 2H), 1.82 (brd, J =12.6, 1H), 
1.71 (q, J = 24.5, 11.9,1H), 1.61-1.54(m, 2H), 1.41-1.33(m, 1H). 13C NMR (125 
MHz, CDCl3) δ 174.71, 135.99, 134.47, 127.32, 121.44, 119.46, 118.10, 110.77, 
108.48, 66.07, 60.55, 60.24, 54.73, 53.30, 51.98, 37.95, 36.56, 33.11, 27.75, 24.60, 
21.73. LRMS (ESI) m/z 355.2 (M + H+), HRMS (ESI) m/z 355.2013, ([M + H+]), 
calc. for [C21H26O3N2 + H




 Reported data2 : 1H NMR(CDCl3, 500 MHz) δ 7.77 (brs, 1H), 7.45 (d, J =7.8, 
1H), 7.27( brd , J =7.8, l H ) , 7.12 (dt , J =1.1, 7.8, lH ) , 7.07 (dt , J =1.1, 7.8, 
1H), 3.99 (dt , J =4.4, 11.0, 1H), 3.83 (s, 3H), 3.13 (dd, J =11.2, 2.1, 1H), 
2.90-3.00(m, 2H), 2.83 (dd, J =11.4, 1.9, 1H), 2.77 (brs, 1H), 2.67 (m, 1H), 2.58 
(dd, J =11.4, 3.0,1H), 2.56 (dd, J =11.0, 4.5, 1H), 2.52 (m, 1 H), 2.42 (ddt, J =12.5, 
3.5, 4.5, 1H), 2.09 (dq, J =13.0, 3.5, 1H), 2.04 ( dq , J =13.0, 3.5, 1H), 1.81 (m, 
1H), 1.70 (dt, J =11.2, 12.5, 1H), 1.61(dt, J =12.5, 3.5, 1H), 1.54 (dq, J =13.0, 3.5, 
1H), 1.35 (ddt, J =11.0, 3.5, 13.0 Hz, 1H); 13C NMR (CDCl3,) δ 174.6, 136.1, 
134.6, 127.4, 121.4, 119.5, 118.1, 110.8, 108.6, 66.1, 60.6,  60.3, 54.9, 53.3, 
51.8,38.1, 36.7, 33.3, 27.8, 24.7, 21.8; mass spectrum, m/e 354.1937 (C21H26N2O3 
requires m/e 354.1943). 
Reported optical rotation3: [α]29D  = -26.0(c1.3, EtOH); [α]
29













References:            
1. Suárez, A.; Fu, G. C. Angew. Chem. Int. Ed. 2004, 43, 3580. 
2. Martin, S. F.; Rueger, H.; Williamson, S. A.; Grzejszczak, S. J. Am. Chem. Soc. 1987, 109, 
6124. 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chiral HPLC Chromatograms 
152 












062008 #151 [modified by TCH] fdw4221 UV_VIS_3
mAU
min
1 - 11.3932 - 12.320
WVL:254 nm
 





















































































































208aa+208ab 11023A.2 Ce2 3005210 

















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   23.07       n.a. 755.450  594.200  31.14     
2   36.73       n.a. 280.832  355.800  18.65     
3   47.05       n.a. 371.223  603.155  31.61     
4   62.59       n.a. 165.165  355.015  18.61     


























No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   23.31       n.a. 415.694  301.873  20.11     
2   47.30       n.a. 695.470  1199.169  79.89     
Total:   1111.164  1501.042  100.00     
 
208ab(11024E)  


















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   37.37       n.a. 66.753  77.490  19.83     
2   62.77       n.a. 149.742  313.194  80.17     
Total:   216.496  390.684  100.00     
 
(6098.3) I A+Ce1 2010210 

















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   10.81       n.a. 128.070  26.615  20.11     
2   12.02       n.a. 111.397  27.096  20.47     
3   13.06       n.a. 137.198  39.752  30.03     




















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   10.87       n.a. 890.852  248.318  91.80     
2   11.98       n.a. 78.836  22.166  8.20     
Total:   969.687  270.485  100.00     
 
 208bb(6106A) 
















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   12.79       n.a. 12.751  3.499  8.56     
2   20.34       n.a. 73.254  37.350  91.44     
Total:   86.005  40.849  100.00     
 
(6083A)  IA1005210 















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   5.43       n.a. 83.255  16.165  36.42     
2   6.06       n.a. 75.527  15.453  34.81     
3   9.26       n.a. 21.429  6.199  13.97     






















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   6.29       n.a. 356.253  100.644  89.69     
2   6.95       n.a. 43.810  11.573  10.31     
Total:   400.063  112.218  100.00     
 
208cb(10183) 

















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   10.15       n.a. 42.171  19.689  11.46     
2   14.99       n.a. 234.569  152.125  88.54     
Total:   276.741  171.815  100.00     
 
 (7173)   IA 1005210 







Template #129 [modified by TCH] UV_VIS_1
mAU
min





No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   12.29       n.a. 1663.108  1110.012  12.96     
2   13.48       n.a. 1592.875  1165.708  13.61     
3   28.09       n.a. 1751.224  3122.662  36.46     
4   35.66       n.a. 1293.867  3165.506  36.96     






















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   11.36       n.a. 829.910  483.929  88.77     
2   12.97       n.a. 101.669  61.198  11.23     
Total:   931.579  545.128  100.00     
 
208db(7176B)  

















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   27.83       n.a. 63.142  57.022  11.42     
2   36.45       n.a. 305.894  442.345  88.58     
Total:   369.036  499.367  100.00     
 
 (7204A)   IA+IA 2010230 

















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   22.57       n.a. 187.129  98.149  35.73     
2   23.77       n.a. 64.880  40.789  14.85     
3   26.14       n.a. 161.353  98.817  35.98     
4   29.95       n.a. 48.909  36.911  13.44     



















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   22.91       n.a. 955.640  652.162  82.54     
2   26.56       n.a. 180.696  137.934  17.46     
Total:   1136.336  790.096  100.00     
208fb (7209)  

















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   23.71       n.a. 15.291  6.643  10.55     
2   29.81       n.a. 76.987  56.344  89.45     
Total:   92.278  62.988  100.00     
 
(7217)  AD+AD  2010230 


















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   26.45       n.a. 253.946  269.899  36.68     
2   32.31       n.a. 236.165  267.775  36.40     
3   35.11       n.a. 80.771  101.649  13.82     
4   46.89       n.a. 39.806  96.409  13.10     




















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   26.41       n.a. 113.000  109.982  15.90     
2   32.08       n.a. 520.009  581.562  84.10     
Total:   633.009  691.544  100.00     
 208gb(7218) 

















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   34.75       n.a. 2.873  1.965  5.10     
2   46.53       n.a. 18.460  36.539  94.90     
Total:   21.332  38.504  100.00     
 
 
 (10257B racemic)  IA0505210 

















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   11.35       n.a. 820.119  442.261  41.73     
2   12.83       n.a. 730.318  453.532  42.80     
3   19.59       n.a. 95.021  82.064  7.74     
4   30.21       n.a. 53.037  81.877  7.73     




















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   11.41       n.a. 572.142  318.666  93.36     
2   12.90       n.a. 42.654  22.660  6.64     
Total:   614.796  341.327  100.00     
 
208hb(Fdw10257B) 


















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   19.67       n.a. 6.486  5.440  5.94     
2   30.17       n.a. 42.169  86.146  94.06     
Total:   48.656  91.586  100.00     
 
(6153A   IC 2010210) 

















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   20.63       n.a. 39.832  31.684  14.49     
2   28.37       n.a. 72.730  78.051  35.70     
3   39.23       n.a. 52.440  77.598  35.49     
4   50.38       n.a. 16.231  31.316  14.32     




















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   27.03       n.a. 31.929  31.876  6.51     
2   36.87       n.a. 314.382  457.704  93.49     
Total:   346.311  489.580  100.00     
 
208ib(6157B) 
















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   19.92       n.a. 10.687  6.298  4.50     
2   47.10       n.a. 73.856  133.622  95.50     
Total:   84.543  139.920  100.00     
 
 
 208haa IC1010230   (fdw10208.2) racemic 
 

















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   14.00       n.a. 39.723  33.897  50.06     
2   18.06       n.a. 31.631  33.813  49.94     

























No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   14.63       n.a. 248.287  253.329  91.68     
2   19.82       n.a. 17.897  22.985  8.32     
Total:   266.184  276.315  100.00     
 
 208hbb IC 1010230  (fdw10208.1) racemic 















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   13.17       n.a. 175.800  135.423  49.98     
2   24.54       n.a. 101.102  135.516  50.02     
Total:   276.902  270.939  100.00     
 
 
fdw11029.1  chiral 
















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   13.77       n.a. 1185.044  1142.111  89.44     
2   27.33       n.a. 80.712  134.839  10.56     









221   (fdw10131)     IC 1010254 racemic  
 














No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   13.17       n.a. 36.508  28.741  49.53     
2   17.69       n.a. 29.468  29.285  50.47     
Total:   65.976  58.026  100.00     
 
fdw10215  chiral 

















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   13.05       n.a. 673.317  635.175  87.81     
2   17.53       n.a. 78.342  88.182  12.19     
Total:   751.659  723.356  100.00     
 
  222   (fdw10130)     IC1010254 racemic 















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   14.36       n.a. 47.588  33.203  48.58     
2   21.03       n.a. 32.812  35.144  51.42     








fdw10217  chiral 















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   14.39       n.a. 10.294  7.729  10.56     
2   21.01       n.a. 58.427  65.490  89.44     
Total:   68.721  73.219  100.00     
 
227  (FDW10207)  AD1010(30mins)->1030230 racemic 















No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   37.93       n.a. 114.622  117.133  51.08     
2   40.85       n.a. 119.569  112.200  48.92     
Total:   234.191  229.334  100.00     
 
FDW10220.2 chiral 














No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
 min  mAU mAU*min % 
1   37.77       n.a. 19.135  16.124  7.33     
2   40.23       n.a. 344.631  203.987  92.67     
 
 
